Application of ITPRIPL1 regulator in preparation of antitumor drugs

Through the modulator of ITPRIPL1, combined with CD3ε and NRP2 receptors, the problem of ITPRIPL1 function regulation in the prior art is solved, effective regulation of tumors and immune responses is achieved, and new immunotherapeutic targets are provided.

CN118924899APending Publication Date: 2024-11-12FUDAN UNIVERSITY +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410920425.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2020-10-30
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The prior art has failed to effectively regulate the function of the ITPRIPL1 protein, resulting in difficulty in inhibiting tumors and regulating immune responses, and lacks the identification and utilization of ITPRIPL1 as an immune checkpoint receptor ligand.

Method used

By developing regulators of ITPRIPL1, including gene editing systems, RNA molecules, recombinant proteins and antibodies, regulate the expression and function of ITPRIPL1, and binds CD3ε and NRP2 receptors to regulate the function of immune cells.

Benefits of technology

Effective regulation of ITPRIPL1 has been achieved, the killing ability of immune cells to tumors is enhanced, and new targets are provided for inhibiting tumor immune escape and regulation of immune response.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924899A_ABST
    Figure CN118924899A_ABST
Patent Text Reader

Abstract

The invention discloses application of an ITPRIPL1 regulator in preparation of anti-tumor drugs, the regulator is used for reducing expression or functions of ITPRIPL1 genes or proteins of tumor cells, and the regulator comprises a gene editing system enabling the ITPRIPL1 genes in the cells to be knocked out or mutated, RNA molecules reducing the expression level of the ITPRIPL1 genes and an antibody recognizing and combining ITPRIPL1. On the basis of new scientific discovery, that is, ITPRIPL1 protein is combined with CD3 epsilon and an NRP2 receptor to regulate functions of different immune cells and further participates in regulation of immune response and an immune escape process of tumors, it is proved that the ITPRIPL1 regulator can be used for preparing anti-tumor drugs or pharmaceutical compositions, and the application of the ITPRIPL1 regulator in preparation of the anti-tumor drugs or pharmaceutical compositions is wide. The compound has an application prospect in the aspect of inhibiting diseases such as tumors, autoimmune diseases, transplant rejection, allergy, infection and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine, and in particular to use of an ITPRIPL1 regulator in the preparation of an anti-tumor drug. Background Art

[0002] The protein encoded by ITPRIPL1 is Inositol 1,4,5-trisphosphate receptor-interactingprotein-like 1. There has been no previous report on the function of ITPRIPL1. According to the annotation of the UniProtKB database, human ITPRIPL1 consists of 555 amino acids, which are divided into the extracellular region (1-103 amino acids), the transmembrane region (104-124 amino acids), and the intracellular region (125-555 amino acids).

[0003] T cells are key effector cells of the adaptive immune response and have many important roles in the elimination of pathogens and autoimmune diseases. There are several subsets of T cells, each with different functions. The TCR (T cell receptor) found on the surface of T cells is a heterodimer composed of α and β polypeptide chains, which make up approximately 95% of the TCR population, or γ and δ polypeptide chains (Pitcher and van Oers, 2003). Each polypeptide contains a constant (C) and a variable (V) region. The constant region is anchored in the cell membrane, while the variable region extends outside the cell and is responsible for binding antigens. The short cytoplasmic tail of the TCR lacks the ability to transduce signals. Intracellular signaling is initiated by the CD3 protein complex, which contains an intracellular immunoreceptor tyrosine-based activation motif (ITAM).

[0004] The CD3 (cluster of differentiation 3) T cell co-receptor is a protein complex consisting of four different chains. In mammals, the complex contains one CD3γ (gamma) chain, one CD3δ (delta) chain, and two CD3ε (epsilon) chains. These chains associate with the TCR and the ζ chain (zeta chain) to generate activation signals in T lymphocytes. Together, the TCR, ζ chain, and CD3 molecules form the TCR complex. The CD3γ, CD3δ, and CD3ε chains are highly related cell surface proteins of the immunoglobulin superfamily that contain a single extracellular immunoglobulin domain. The TCR cannot bind to free epitopes / antigens, instead, the TCR binds to enzymatically cleaved fragments of larger polypeptides associated with the major histocompatibility complex (MHC), synonymous with the human leukocyte antigen (HLA) system in humans. This interaction occurs in a space known as the immunological synapse. Class I MHC molecules are expressed on all nucleated cells in the human body and present antigens to cytotoxic T cells, which CD8 on these cytotoxic T cells stabilizes the MHC / TCR interaction. Activation of cytotoxic T cells subsequently leads to the destruction of target cells. Class II MHC is found on macrophages, B cells, and dendritic cells. These immune cells present antigens to helper T cells with CD4 that stabilizes the MHC / TCR interaction. The interaction between MHC class II and TCR ultimately results in an antibody-mediated immune response. Other co-stimulatory molecules such as CD45, CD28, and CD2 contribute to T cell activation in the immunological synapse and initiate the formation of the TCR signalosome, a large protein complex responsible for intracellular signaling.

[0005] Several antibodies that bind to human CD3ε have been reported, such as antibody OKT3 (see, e.g., Kung, P. et al., Science 206 (1979) 347-349; Salmeron, A. et al., J Immunol 147 (1991) 3047-3052), antibody UCHT1 (see, e.g., Callard, RE et al., Clin Exp Immunol 43 (1981) 497-505) or antibody SP34 (see, e.g., Pessano, S. et al., EMBO J 4 (1985) 337-344). Among the currently known antibodies, SP34 is cross-reactive with human cynomolgus monkey (Conrad ML et al., Cytometry A 71 (2007) 925-933). Previously, proteins known to directly bind to the extracellular region of CD3ε were all antibody molecules, and there have been no reports of natural non-antibody proteins (such as transmembrane proteins, secretory proteins and other typical ligands) binding to the extracellular region of CD3ε.

[0006] Neuropilin-2, or NRP-2, is a receptor that can regulate the function of immune cells (AmJPhysiol Lung Cell Mol Physiol. 2018). It is reported to regulate the function of antigen-presenting cells and promote tumor immune escape (Sohini Roy et al., Cancer Res. 2018); NRP2 can affect the migration and phagocytic function of immune cells, as well as the contact between immune cells (S Schellenburg et al., Mol Immunol. 2017). The co-receptor formed by NRP2 and Plexin has an anti-chemotactic effect on the migration of lymphatic endothelial cells (Liu X et al., Cell Rep. 2016). NRP2 can also regulate the NFKB signaling pathway of cells, as reported in (Rizzolio, S. et al. Cancer Research. 2017). Previously discovered NRP2 ligands include members of the Semaphorin family, but other types of ligands have not been reported. Summary of the invention

[0007] The purpose of the present invention is to provide a method for regulating immune response and inhibiting tumors, and use of an ITPRIPL1 regulator in preparing drugs for regulating immune response or inhibiting tumors.

[0008] In order to achieve the above object, the present invention provides the use of an ITPRIPL1 regulator in the preparation of a drug for regulating immune response or anti-tumor, wherein the regulator is used to increase or decrease the expression or function of the ITPRIPL1 gene or protein of the body.

[0009] Preferably, the regulator comprises any one of the following:

[0010] (1) A gene editing system that knocks out or mutates the ITPRIPL1 gene in cells;

[0011] (2) RNA molecules that reduce the expression level of the ITPRIPL1 gene;

[0012] (3) a nucleic acid molecule for introduction into a cell, wherein the nucleic acid molecule encodes ITPRIPL1 and increases the expression level of ITPRIPL1;

[0013] (4) isolated ITPRIPL1 recombinant protein;

[0014] (5) Antibodies that recognize and bind to ITPRIPL1.

[0015] Preferably, the gene editing system is a CRISPR / Cas9 gene editing system; the target sequence used for the CRISPR / Cas9 gene editing system is selected from any one of the sequences shown in SEQ ID NO:11-13, and the oligomeric DNA sequence used to encode sgRNA is selected from SEQ ID NO:14-19; the nucleic acid molecule comprises: a sequence shown in SEQ ID NO:8, SEQ ID NO:9 or SEQ ID NO:10; the ITPRIPL1 recombinant protein comprises: a functional fragment in the extracellular region of the ITPRIPL1 protein that can bind to CD3ε or NRP2 protein; the antibody that recognizes and binds to ITPRIPL1 is a polyclonal antibody, a monoclonal antibody, a single-chain antibody, an antigen binding domain, a bispecific antibody, a multispecific antibody, or an antigen binding portion in a chimeric antigen receptor.

[0016] Preferably, the sequence of the functional fragment is selected from any one of SEQ ID NO: 1 to SEQ ID NO: 4, or a derivative sequence thereof, and the derivation method includes: replacing, deleting or inserting one or more amino acids without changing the function of the sequence.

[0017] Preferably, the ITPRIPL1 recombinant protein forms a fusion protein with an antibody constant region (as shown in SEQ ID NOs: 5-7) or forms a fusion protein with a coagulation factor; alternatively, the ITPRIPL1 recombinant protein is modified, and the modification methods include: polyethylene glycol modification, glycosylation modification, polysialic acid modification, fatty acid modification, KLH modification, and biotin modification.

[0018] Preferably, the nucleic acid molecule is introduced into the cell via a drug delivery system, and the drug delivery system includes: a recombinant expression vector, a virus, a liposome or a nanomaterial.

[0019] Preferably, the regulation of immune response includes: regulation of the functions of antigen presenting cells and T lymphocytes in the process of autoimmune response, inhibition of transplant rejection immune response, allergic response, anti-infection immune response and anti-tumor immune response.

[0020] Preferably, the immune response includes: type I diabetes, immune infertility, rejection after organ transplantation, allergic reaction, systemic inflammation or cytokine storm, infection.

[0021] Preferably, the tumor is a solid tumor or a hematological tumor; the solid tumor includes: glioma, lung cancer, head and neck cancer, gastric cancer, colorectal cancer, thyroid cancer, esophageal cancer, urothelial cancer, testicular cancer, breast cancer, cervical cancer, endometrial cancer, melanoma, pancreatic cancer or liver cancer; the hematological tumor includes: leukemia or lymphoma.

[0022] The present invention also provides a pharmaceutical composition, which comprises the regulator used in the above-mentioned use and a pharmaceutically acceptable carrier.

[0023] The present invention also provides a separated ITPRIPL1 recombinant protein, wherein the recombinant protein is a functional fragment in the extracellular region of the ITPRIPL1 protein that can bind to CD3ε or NRP2 protein.

[0024] The present invention also provides an antibody that recognizes and binds to ITPRIPL1, wherein the antibody recognizes and binds to the extracellular region of ITPRIPL1 protein.

[0025] The present invention also provides a method for identifying the above-mentioned antibodies, by detecting one or more of the following properties of the test antibody: the ability to specifically bind to ITPRIPL1 protein; the effect on the binding of ITPRIPL1 to CD3ε; the effect on the binding of ITPRIPL1 to NRP2; the effect on the function of immune cells or tumor cells.

[0026] The present invention also provides the use of the isolated ITPRIPL1 recombinant protein for detecting the presence of autoanti-ITPRIPL1 antibodies, wherein the main steps of the detection include directly contacting the ITPRIPL1 recombinant protein with a blood sample of a subject, and washing to remove non-specific binding.

[0027] The present invention also provides the use of the above-mentioned antibodies for detecting the content of ITPRIPL1 in a sample, and the antibodies that recognize and bind to ITPRIPL1 are used to determine the expression of ITPRIPL1 in cells, tissues, organs or individuals, or to determine whether the method of regulating immune response and inhibiting tumors by targeting ITPRIPL1 of the present invention is suitable for application.

[0028] Compared with the prior art, the present invention has the following beneficial effects:

[0029] The present invention discloses a method for regulating immune response and inhibiting tumors, and the above-mentioned purpose is achieved by regulating the expression or function of the ITPRIPL1 gene. The present invention is based on a new scientific discovery that the ITPRIPL1 protein binds to CD3ε and NRP2 receptors to regulate the functions of different immune cells, thereby participating in the regulation of immune response and the immune escape process of tumors. The present invention confirms that the regulator of ITPRIPL1 can be used to prepare drugs or pharmaceutical compositions, and has application prospects in inhibiting tumors, autoimmune diseases, transplant rejection, allergies and infections. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 This is the plasmid construction result of Example 1.

[0031] Figure 2 The immunoprecipitation results of Example 1 are shown in FIG.

[0032] Figure 3 This is a diagram showing the co-localization of exogenously expressed ITPRIPL1 and CD3E in cells in Example 1.

[0033] Figure 4 This is the result of constructing the expression vector expressing the receptor binding domain of the ITPRIPL1 extracellular region in Example 2.

[0034] Figure 5 The immunoprecipitation results of Example 2 are shown in FIG.

[0035] Figure 6 The results of immunofluorescence and colocalization analysis in Example 2 show that the ITPRIPL1 extracellular region and the CD3 extracellular region have trans-binding activity.

[0036] Figure 7 This is the Coomassie Brilliant Blue staining result after gel electrophoresis of the ITPRIPL1-RBD recombinant protein (IT1-RBD protein) in Example 3.

[0037] Figure 8 The ELISA test results of Example 4 are shown in FIG.

[0038] Fig. 9 and Fig.10 This is a result diagram of flow cytometry in Example 5 demonstrating that the purified protein fragment of the extracellular region of ITPRIPL1 binds to Jurkat cells that highly express CD3, wherein: Fig. 9 (a) is the threshold setting for not classifying dead cells. Fig. 9 (b) reflects the binding of Jurkat cells to different concentrations of purified protein fragments of the extracellular region of ITPRIPL1. Fig.10 Then Fig. 9 Specific staining and protein binding conditions under (b).

[0039] Fig.11 and Fig.12 This is a result diagram of flow cytometry in Example 5 proving that ITPRIPL1 protein binds to cells overexpressing CD3 with higher efficiency, wherein: Fig.11 (a) is the threshold setting for not classifying dead cells. Fig.11 (b) reflects the binding of cells with different CD3ε expression levels to different concentrations of ITPRIPL1 recombinant protein. Fig.12 Then Fig.11 Specific staining and protein binding conditions under (b).

[0040] Fig.13 and Fig.14This is a result diagram of flow cytometry in Example 5 demonstrating that CD3 binds to cells overexpressing ITPRIPL1 with higher efficiency, wherein: Fig.13 (a) is the threshold setting for not classifying dead cells. Fig.13 (b) reflects the binding of cells with different ITPRIPL1 expression levels to CD3ε protein. Fig.14 They are Fig.13 Specific staining and protein binding conditions under (b).

[0041] Fig.15 This is a graph showing the change in NFKB signal with changes in ITPRIPL1 protein concentration under the condition of 50 μg / ml ConA activation in Example 5.

[0042] Fig.16 This is a graph showing the change in NFKB signal as the concentration of ITPRIPL1 protein coated on the microspheres changes under the condition of 50 μg / ml ConA activation in Example 5.

[0043] Fig.17 The expression of ITPRIPL1 in different types of tumor cells after adjustment with GAPDH as the internal reference in immunoblotting.

[0044] Fig.18 The figure shows the mRNA expression level of ITPRIPL1 in normal tissues and tumor tissues.

[0045] Fig.19 This is a diagram showing the results of the enzyme-linked immunosorbent assay in Example 6, which demonstrates that the polyclonal antibody can bind to cells expressing ITPRIPL1.

[0046] Fig. 20 This is a diagram showing the result of the enzyme-linked immunosorbent assay in Example 6, which proves that the polyclonal antibody can block the binding of ITPRIPL1 to CD3E.

[0047] Fig.21 and Fig. 22 This is a result diagram of flow cytometry in Example 6 proving that the polyclonal antibody can block the binding of ITPRIPL1 to cells overexpressing CD3ε, wherein: Fig.21 (a) is the threshold setting for not classifying dead cells. Fig.21 (b) reflects the changes in the binding between ITPRIPL1 and CD3ε when the concentration of polyclonal antibodies changes. Fig. 22 Then Fig.21 Specific staining and protein binding conditions under (b).

[0048] Fig.23This is a graph showing the results of the luciferin reporter experiment in Example 7, which proves that HCT116 cells overexpressing ITPRIPL1 can further reduce the NFKB proliferation signal of Jurkat-dual cells.

[0049] Fig.24 This is a graph showing the results of the luciferin reporter experiment in Example 7, which proves that CD3E protein can block the inhibition of ITPRIPL1 protein on the NFKB proliferation signal of Jurkat-dual cells.

[0050] Fig.25 and Fig.26 This is a result diagram of flow cytometry in Example 8 proving that ITPRIPL1-RBD recombinant protein can reduce the killing of human peripheral blood mononuclear cells (PBMC) on kidney-derived H3K293 cells, wherein: Fig.25 (a) and (b) show the classification of 293E cells based on CD45. Fig.25 (c) is the relative killing activity of PBMC calculated based on the apoptosis data of each group under different ITPRIPL1 protein concentrations. Fig.26 for Fig.25 Specific apoptosis staining under each condition in (c).

[0051] Fig. 27 and Fig.28 This is a result diagram of flow cytometry in Example 9 proving that overexpression of ITPRIPL1 can reduce the killing of tumor cells by PBMC, while knocking out ITPRIPL1 can promote the killing of tumor cells by PBMC, wherein: Fig. 27 (a) and (b) show the classification of HCT116 cells based on CD45. Fig. 27 (c) is the relative killing activity of PBMC calculated based on the apoptosis data of each group under different polyclonal antibody concentrations. Fig.28 for Fig. 27 Specific apoptosis staining under each condition in (c).

[0052] Fig.29 and Fig.30 This is a graph showing the results of flow cytometry in Example 10, demonstrating that ITPRIPL1 polyclonal antibody can promote the killing of tumor cells by PBMC. Fig.29 (a) and (b) show the classification of HCT116 cells based on CD45. Fig.29 (c) is the relative killing activity of PBMC calculated based on the apoptosis data of each group under different polyclonal antibody concentrations. Fig.30 for Fig.29 Specific apoptosis staining under each condition in (c).

[0053] Fig.31The immunoprecipitation results of Example 11 are shown.

[0054] Fig.32 This is a diagram showing the results of the enzyme-linked immunosorbent assay of Example 12.

[0055] Fig.33 and Fig.34 The experimental results of Example 12 using flow cytometry prove that NRP2 binds to cells overexpressing ITPRIPL1 with higher efficiency. Fig.33 (a) is the threshold setting for not classifying dead cells. Fig.33 (b) reflects the binding of cells with different ITPRIPL1 expression levels to NRP2 protein. Fig.34 They are Fig.33 Specific staining and protein binding conditions under (b).

[0056] Fig.35 The experimental results for luciferin in Example 13 are reported.

[0057] Fig.36 The experimental results for luciferin of Example 14 are reported.

[0058] Fig.37 and Fig.38 This is a result diagram showing that the purified IT1-RBD1-Fc recombinant protein can reduce the killing of human peripheral blood mononuclear cells (PBMC) on kidney-derived H3K293 cells by flow cytometry in Example 14, wherein: Fig.37 (a) shows the classification of 293E cells based on CD45. Fig.37 (b) is the relative killing activity of PBMC calculated based on the apoptosis data of each group under different ITPRIPL1 expression and different protein conditions. Fig.38 for Fig.37 Specific apoptosis staining under each condition in (b).

[0059] Fig.39 The immunoblotting results of Example 14 are shown. DETAILED DESCRIPTION

[0060] The following describes the embodiments of the present invention through specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention.

[0061] Before further describing the specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are for describing the specific embodiments rather than for limiting the scope of protection of the present invention; in the present specification and claims, unless otherwise expressly stated herein, the singular forms "a", "an" and "the" include plural forms.

[0062] When the embodiments give numerical ranges, it should be understood that, unless otherwise specified in the present invention, both endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those generally understood by those skilled in the art. In addition to the specific methods, equipment, and materials used in the embodiments, according to the grasp of the prior art by those skilled in the art and the record of the present invention, any methods, equipment, and materials of the prior art similar or equivalent to the methods, equipment, and materials described in the embodiments of the present invention can also be used to realize the present invention.

[0063] The present application is further described below by way of examples, but the scope of the present application is not limited thereby. Unless otherwise specified, the experimental methods, detection methods, and preparation methods disclosed in the present invention all adopt conventional techniques in molecular biology, biochemistry, chromatin structure and analysis, analytical chemistry, cell culture, recombinant DNA technology, and related fields conventional in the art. These techniques have been fully described in existing literature.

[0064] The technical solution of the present invention is further described below in conjunction with the accompanying drawings and embodiments.

[0065] The present invention discloses for the first time that the extracellular region of ITPRIPL1 binds to the extracellular region of CD3ε and the extracellular region of NRP2, and discloses the regulatory effects of ITPRIPL1 on T cells and antigen presenting cells after binding to CD3ε and NRP2, respectively. Based on new scientific discoveries, the present invention discloses a method for regulating immune response and inhibiting tumors by targeting ITPRIPL1, and discloses the use of ITPRIPL1 regulators in the preparation of drugs for regulating immune response or anti-tumor. Specifically, the present invention provides a method for editing the ITPRIPL1 gene, and a method for introducing genetic material into cells to regulate the expression of ITPRIPL1. The present invention further discloses the receptor binding domain (RBD) of ITPRIPL1 and provides a scheme for preparing ITPRIPL1-RBD isolated protein, and demonstrates a method for regulating the function of immune cells by binding to CD3ε and NRP2 with ITPRIPL1-RBD. Further, the present invention illustrates a method for preparing ITPRIPL1 antibodies, and proves that the above antibodies can enhance the anti-tumor effect of immune cells. The method disclosed in the present invention for regulating immune response and inhibiting tumor by targeting ITPRIPL1 shows the target value of ITPRIPL1 in treating tumors, autoimmune diseases, transplant rejection, allergic reactions, infections and other diseases.

[0066] There have been no reports on the function of the ITPRIPL1 gene in the past. The present invention discloses ITPRIPL1 as a newly identified ligand for CD3ε (Example 1), clarifies that the ITPRIPL1 extracellular region receptor binding domain (RBD) is amino acids 25-103 (Example 2), and on this basis prepares an isolated recombinant protein with the function of regulating CD3ε and T cells (Example 3). The present invention also discloses the preparation, use and administration method of the above isolated protein.

[0067] Furthermore, the present invention discloses the ability of the isolated ITPRIPL1-RBD protein to bind to CD3ε (Example 4), and uses enzyme-linked immunosorbent assay (ELISA), flow cytometry and other experimental methods to prove that the ITPRIPL1-RBD isolated protein can bind to the extracellular region of CD3ε.

[0068] Since ITPRIPL1-RBD (sequence see SEQ ID NO: 1) is the key region for binding to CD3ε, an isolated ITPRIPL1-RBD protein can be prepared by recombinant expression, which can be used to bind to CD3ε protein on the cell surface and transmit inhibitory signals to T cells (Example 5), so the isolated ITPRIPL1-RBD protein can be used to regulate the function of T cells. Although the present invention provides the effect of an isolated protein with a sequence of SEQ ID NO: 1 on binding to CD3ε, regulating T cells and preparing neutralizing antibodies, other protein sequences with similar functions obtained by non-creative derivation methods (such as truncation, insertion, mutation or fusion, etc.) that are easily implemented by those skilled in the art are also within the scope of the rights claimed by the present invention.

[0069] The present invention discloses the use of separated ITPRIPL1-RBD as an immunogen to prepare neutralizing antibodies (Example 6). In the case where ITPRIPL1 is not revealed as a ligand for CD3ε, technicians in this field cannot purposefully prepare antibodies for blocking the binding of ITPRIPL1 and CD3. The present invention reveals the existence of a pair of receptor ligands, CD3ε and ITPRIPL1, defines the key structure of ITPRIPL1 binding to CD3, and provides a method for preparing an ITPRIPL1-RBD isolated protein, which makes the preparation of antibodies for blocking the binding of ITPRIPL1 and CD3 an easy goal for those in this field to achieve through conventional techniques (such as hybridoma, phage display and other technologies). Therefore, the blocking antibody prepared using the ITPRIPL1 extracellular region fragment as an immunogen is also within the scope of the claims of the present patent application.

[0070] The present invention also discloses that the activation of proliferation signaling pathway of T cell-derived cell lines can be regulated by regulating the binding between ITPRIPL1-RBD and the extracellular region of CD3 (Example 7).

[0071] The present invention discloses that ITPRIPL1-RBD recombinant protein can reduce the killing of human peripheral blood mononuclear cells (PBMC) to kidney-derived H3K293 cells (Example 8), and accordingly proposes the application of targeting ITPRIPL1 in inhibiting autoimmunity, as well as the application value in preparing a pharmaceutical composition for treating autoimmunity, transplant rejection, allergy, infection and other diseases.

[0072] The present invention reveals that reducing the expression of ITPRIPL1 in tumor cells can significantly increase the killing of tumor cells by human peripheral blood mononuclear cells (Example 9), supporting the role of ITPRIPL1 in tumor immune escape, and thus proposing the important value of ITPRIPL1 as a target for tumor immunotherapy.

[0073] The present invention also reveals that antibodies prepared using ITPRIPL1-RBD protein as an immunogen effectively promote the killing of tumor cells by immune cells (Example 10). This verifies the important value of ITPRIPL1 as a target for tumor immunotherapy, and establishes a method for blocking the binding of ITPRIPL1 and CD3 with antibodies. The antibodies represent a class of antibodies with a completely new function, namely antibodies that recognize ITPRIPL1 and block its binding to CD3ε, thereby regulating T cell function.

[0074] Furthermore, the present invention compared ITPRIPL1 extracellular region fragments of different lengths, demonstrating that the ITPRIPL1-RBD2 sequence has the ability to bind to CD3ε but is slightly reduced, while the ability of ITPRIPL1-RBD3 to bind to CD3 is significantly reduced, thereby revealing the positive correlation between the length of the ITPRIPL1 extracellular region and the CD3ε binding ability, characterizing the basic characteristics of the functional ITPRIPL1 extracellular region sequence (Example 11).

[0075] The present invention discloses that the ITPRIPL1-RBD protein has the ability to bind to NRP2 (Example 12). The isolated ITPRIPL1-RBD protein has the ability to transmit inhibitory signals to differentiated THP1 macrophages expressing NRP2 protein (Example 13). At the same time, the purified IT1-RBD-Fc protein has the function of inhibiting T cell signals and killing (Example 14).

[0076] The sequence list used in the present invention is as follows:

[0077] Table 1

[0078]

[0079]

[0080]

[0081]

[0082] Example 1: ITPRIPL1 as a newly identified ligand for CD3ε

[0083] 1. Construction of expression plasmid

[0084] Based on the published sequence (NCBI reference sequence NM_001008949.3), the full-length human ITPRIPL1 cDNA was synthesized using pcDNA3.1 as the vector, in which the C-terminus was fused to the Flag tag, thereby generating an ITPRIPL1 plasmid containing a Flag tag. The plasmid construction results are shown in Figure 1 shown. Figure 1(a) is a schematic diagram of the vector cloning structure. Figure 1 (b) is the DNA gel electrophoresis diagram after the gene expression vector plasmid was digested by EcoRI / XhoI. The size of the obtained fragments is consistent with the expectation. Figure 1 (c) is a partial excerpt of the vector sequencing verification results.

[0085] 2. The results of immunoprecipitation and immunoblotting analysis showed that ITPRIPL1 binds to CD3.

[0086] pcDNA3.1 plasmids containing Flag-tagged ITPRIPL1 (or empty vector) and HA-tagged CD3ε were co-transfected into HCT116 cells (ATCC, VA, USA) and cultured in six-well plates (Corning, NY, USA) for 48-72 hours until the proteins were fully expressed. The cells were then lysed and scraped using a 1:100 immunoprecipitation lysis buffer (Thermo Fisher, MA, USA) mixed with a protease, phosphatase, and PMSF triple combination (Conson, Shanghai, China). A portion of the cell samples was centrifuged, mixed with a loading buffer (Beyotime, Shanghai, China), and denatured in a metal bath at 100 degrees Celsius to obtain the input protein sample; the remaining cell samples were immunoprecipitated with a Flag-tag-specific mouse antibody (CST, MA, USA), washed with PBS, mixed with a loading buffer (Beyotime, Shanghai, China), and denatured in a metal bath at 100 degrees Celsius to obtain the immunoprecipitated protein sample. Then, according to the instructions, 12.5% ​​PAGE gel (Yazyme, Shanghai, China) was prepared in a gel plate (Bio-Rad, CA, USA), and the prepared gel was placed in an electrophoresis tank (Bio-Rad, CA, USA). The power supply (Bio-Rad, CA, USA) was connected to allow the strip to run through the concentrated gel at a constant voltage of 80 volts and the separation gel at a constant voltage of 120 volts. When the strip ran to the bottom of the separation gel, the wet transfer was performed, and the transfer tank (Bio-Rad, CA, USA) was used for 90 minutes at a constant current of 350 mA. After the transfer was completed, the membrane was cut according to the mass size of ITPRIPL1-Flag and CD3ε-HA proteins. The membrane was blocked with a rapid blocking solution (Yazyme, Shanghai, China) for ten minutes, and the corresponding bands of ITPRIPL1-Flag and CD3ε-HA were incubated with Flag tag-specific rabbit antibodies (Abcam, MA, USA) and HA tag-specific rabbit antibodies (CST, MA, USA) respectively, at 4°C overnight. The next day, after washing with TBST, the sections were incubated with specific anti-rabbit secondary antibody (Conson, Shanghai, China) diluted in 5% skim milk (Sangon, Shanghai, China) dissolved in TBS for one hour at room temperature, washed with TBST, placed in mixed luminescent solution (Shenger, Shanghai, China) for one minute, and exposed under a gel imager (Bio-Rad, CA, USA).

[0087] like Figure 2 The results of co-immunoprecipitation experiments are shown. Figure 2(a) and (b) respectively show the contents of ITPRIPL1 and CD3ε in the input proteins used for co-immunoprecipitation, i.e., the input amount. Figure 2 (c) shows directly precipitated ITPRIPL1, Figure 2 (d) shows indirectly precipitated CD3ε bound to ITPRIPL1. The results of co-immunoprecipitation experiments indicate that ITPRIPL1 binds to CD3.

[0088] 3. Immunofluorescence and colocalization analysis showed that ITPRIPL1 and CD3 had significant colocalization.

[0089] The pcDNA3.1 plasmid containing Flag-tagged ITPRIPL1 (or empty vector) and HA-tagged CD3ε was co-transfected into HCT116 cells (ATCC, VA, USA), placed on an eight-well glass slide (Thermo Fisher, MA, USA) and cultured for 30 hours until the protein was fully expressed, then the culture medium was discarded, washed with PBS, fixed with 4% paraformaldehyde for 20 minutes, washed again with PBS, blocked with permeabilization blocking solution for one hour, and then added with Flag tag-specific mouse antibody (CST, MA, USA) and HA tag-specific rabbit antibody (CST, MA, USA) diluted with permeabilization blocking solution and incubated overnight at 4°C. After washing with PBS overnight, the eight-well glass slide was added with PBS-diluted AlexaFluor 488 fluorescent-specific anti-mouse antibody (Invitrogen, CA, USA) and Alexa Fluor 594 fluorescent-specific anti-rabbit antibody (Invitrogen, CA, USA) and incubated at room temperature for 20 minutes, washed with PBS, mounted with DAPI, and observed under a fluorescence microscope after the mounting medium dried.

[0090] Figure 3 The results showed that exogenously expressed ITPRIPL1 significantly co-localized with CD3ε in cells. Figure 3 (a) is the localization pattern of ITPRIPL1; (b) is the localization pattern of CD3ε protein; (c) is the superposition of the two color protein localization patterns, where the fluorescence intensity of ITPRIPL1 and CD3ε on the white straight line path is Figure 3 (d) shows that the localization of the two proteins is significantly correlated, which supports the mutual binding of the two proteins.

[0091] Example 2: The receptor binding domain (RBD) of the ITPRIPL1 extracellular region is amino acids 25-103

[0092] 1. Construction of expression plasmid

[0093] Based on the published sequence (NCBI reference sequence NM_001008949.3), the extracellular region (25-103 amino acids), the extracellular region and transmembrane region (25-124 amino acids), and the transmembrane region and intracellular region (104-555 amino acids) were selected as three different target sequences to synthesize the full-length human ITPRIPL1, using pcDNA3.1 as the vector, wherein the C-terminus of the extracellular region, the extracellular region and the transmembrane region were fused to the Flag tag and green fluorescent protein (GFP), and the N-terminus of the transmembrane region and the intracellular region were fused to the Flag tag and green fluorescent protein (GFP), thereby generating the ITPRIPL1 extracellular region, extracellular region and transmembrane region, and transmembrane region and intracellular region plasmids containing the Flag tag and green fluorescent protein (GFP). Among them, the expression vector construction result of ITPRIPL1 (25-103), i.e., the CD3 binding domain, is shown in the figure. Figure 4 shown. Figure 4 (a) is a vector plasmid construction map. The cDNA encoding the amino acid fragment of ITPRIPL1 (25-103) was linked to the cDNA encoding the Flag tag at all ends and inserted into pEGFP-C1 (Shanghai Jierui Company). The expression product of this vector is labeled with GFP fluorescence, but its main functional product is ITPRIPL1 (25-103), the CD3 binding fragment. Figure 4 (b) is the DNA gel electrophoresis diagram after the gene expression vector plasmid was digested by EcoRI / XhoI. The size of the obtained fragments is consistent with the expectation. Figure 4 (c) is a screenshot of the peak graph of the sequencing results.

[0094] 2. The results of immunoprecipitation experiments showed that the extracellular region of ITPRIPL1 (but not the intracellular region or transmembrane region) binds to CD3ε.

[0095] The pcDNA3.1 plasmids containing the extracellular region, extracellular region and transmembrane region, intracellular region and transmembrane region of ITPRIPL1 with a Flag tag, and CD3ε with a HA tag were co-transfected into HCT116 cells (ATCC, VA, USA) and cultured in six-well plates (Corning, NY, USA) for 48-72 hours until the protein was fully expressed. The cells were then lysed and scraped using a 1:100 immunoprecipitation lysis buffer (Thermo Fisher, MA, USA) mixed with a triple combination of protease, phosphatase, and PMSF (Conson, Shanghai, China). A portion of the cell samples were centrifuged, mixed with a loading buffer (Beyotime, Shanghai, China), and denatured in a metal bath at 100 degrees Celsius to obtain the input protein sample; the remaining cell samples were immunoprecipitated with a Flag tag-specific mouse antibody (CST, MA, USA), washed with PBS, mixed with a loading buffer (Beyotime, Shanghai, China), and denatured in a metal bath at 100 degrees Celsius to obtain the immunoprecipitated protein sample. Then, according to the instructions, 12.5% ​​PAGE gel (Yazyme, Shanghai, China) was prepared in a gel plate (Bio-Rad, CA, USA), and the prepared gel was placed in an electrophoresis tank (Bio-Rad, CA, USA). The power supply (Bio-Rad, CA, USA) was connected to run the strip through the concentrated gel at a constant voltage of 80 volts and the separation gel at a constant voltage of 120 volts. When the strip ran to the bottom of the separation gel, the wet transfer was performed, and the transfer tank (Bio-Rad, CA, USA) was used for 90 minutes at a constant current of 350 mA. After the transfer was completed, the membrane was cut according to the mass size of ITPRIPL1 extracellular region, extracellular region and transmembrane region, intracellular region and transmembrane region-Flag and CD3ε-HA protein. After blocking with fast blocking solution (YaZe, Shanghai, China) for ten minutes, the corresponding bands of ITPRIPL1-Flag and CD3ε-HA were incubated with Flag tag-specific rabbit antibody (Abcam, MA, USA) and HA tag-specific rabbit antibody (CST, MA, USA) respectively, at 4°C overnight. The next day, after washing with TBST, the membrane was incubated with specific anti-rabbit secondary antibody (Kangchen, Shanghai, China) diluted with 5% skim milk powder (Shenggong, Shanghai, China) dissolved in TBS for one hour at room temperature, washed with TBST, placed in mixed luminescent solution (Shenger, Shanghai, China) for one minute, and exposed under a gel imager (Bio-Rad, CA, USA).

[0096] Figure 5 The results of the immunoprecipitation experiment. Figure 5 As shown, Figure 5 (a) shows the amount of ITPRIPL1 in the input protein detected by the Flag antibody, while Figure 5 (b) shows the content of CD3ε in the input protein amount. Figure 5 (c) shows the direct precipitation of different mutants of ITPRIPL1, while Figure 5(d) shows the corresponding CD3ε that was indirectly precipitated (due to binding to ITPRIPL1 mutant). The above results show that CD3ε and ITPRIPL1 remain bound in the presence of the extracellular region of ITPRIPL1 (rather than the intracellular region or transmembrane region). Therefore, the extracellular region of ITPRIPL1 binds to CD3ε, which is consistent with the conclusion that the CD3ε ligand ITPRIPL1 has an extracellular region receptor binding domain (RBD) of amino acids 25-103.

[0097] 3. Immunofluorescence and co-localization analysis showed that the extracellular domains of ITPRIPL1 and CD3 had trans-binding.

[0098] HA-tagged CD3ε was transfected into HCT116 cells; in addition, the pcDNA3.1 plasmid of ITPRIPL1 (extracellular region and transmembrane region)-green fluorescent protein with Flag tag was transfected into another batch of HCT116; finally, the cells transfected twice were co-cultured, and the localization pattern of the two proteins was determined by immunofluorescence double staining. The specific steps are as follows: a batch of HCT116 cells (ATCC, VA, USA) were transfected with pcDNA3.1 plasmid containing HA tag CD3ε; in addition, a batch of HCT116 cells (ATCC, VA, USA) were transfected with pcDNA3.1 plasmid containing ITPRIPL1 (extracellular region and transmembrane region)-green fluorescent protein with Flag tag were transfected into another batch of HCT116 cells (ATCC, VA, USA); 20 hours after transfection, the cells were digested with trypsin, mixed and fully resuspended, plated on eight-well slides (Thermo Fisher, MA, USA), and cultured for 10 hours. The culture medium was discarded, and the slides were fixed with 4% paraformaldehyde for 20 minutes after washing with PBS. After washing with PBS again, the slides were blocked with membrane blocking solution for one hour, and then HA tag-specific rabbit antibody (CST, MA, USA) diluted with membrane blocking solution was added and incubated overnight at 4°C. After washing with PBS overnight, Alexa Fluor594 fluorescent-specific anti-rabbit antibody (Invitrogen, CA, USA) diluted with PBS was added to the eight-well slides and incubated at room temperature for 20 minutes. After washing with PBS, the slides were sealed with DAPI and observed under a fluorescence microscope after the sealing solution dried. The localization pattern of the two proteins was determined by immunofluorescence double staining.

[0099] like Figure 6 As shown, Figure 6 (a) shows an image of ITPRIPL1 and CD3ε staining overlap, Figure 6 (b) and (c) show the staining results of ITPRIPL1 receptor binding region (ITPRIPL1-RBD) and CD3ε, respectively. Figure 6(d) is the area where the two proteins co-localize, obtained by analyzing the co-localization analysis module of the ImageJ software package. The fluorescence intensity of ITPRIPL1 and CD3ε on the white straight line path is Figure 6 (e) shows that at the junction of two cells, the signals of ITP-RBD (green fluorescence) and CD3ε (red fluorescence) are obviously concentrated and enhanced, which supports the trans-binding of the extracellular regions of the two proteins on the cell surface.

[0100] Example 3: Preparation of ITPRIPL1-RBD isolated recombinant protein with CD3ε and T cell regulation function

[0101] The human ITPRIPL1 extracellular region (25-103 amino acids) recombinant protein was synthesized by Cusabio (Wuhan, China) based on the published sequence (NCBI reference sequence NP_001008949.1), expressed and purified by yeast, and the C-terminus was fused to 6x-His and Myc tags to produce ITPRIPL1-RBD recombinant protein containing 6x-His and Myc tags.

[0102] like Figure 7 The figure shows the results of Coomassie brilliant blue staining after gel electrophoresis of ITPRIPL1-RBD recombinant protein, indicating that its molecular weight and purity are in line with expectations.

[0103] Example 4: ConA and isolated ITPRIPL1-RBD protein have the ability to bind to CD3ε

[0104] Enzyme-linked immunosorbent assay (ELISA) confirmed that concanavalin A (ConA) and the isolated ITPRIPL1 extracellular region fragments respectively had a concentration-dependent direct binding to the CD3ε extracellular region. ELISA special plates (costar, ME, USA) were used. First, 0.5 / 1 / 2 / 4 μg / ml ConA or 0.03125 / 0.0625 / 0.125 / 0.25 / 0.5 / 1 / 2 μg / ml ITPRIPL1-RBD recombinant protein were dissolved in 100 μl ELISA coating solution (Solarbio, Beijing, China) for coating, and 100 μl of protein-free coating solution was used for negative control. Coating was performed overnight at four degrees. After washing with PBST, 100 μl of 5% BSA (VWR, PA, USA) dissolved in PBS was used for blocking, and the plate was blocked in an incubator at 37 degrees for 90 minutes. After washing with PBST, the cells were incubated with 1 μg / mL CD3ε extracellular region protein fragment (Sino Biological, Beijing, China), which has an hFc tag, for 60 minutes at 37 degrees. After washing with PBST, the cells were incubated with specific anti-human Fc fragment antibody (Abcam, MA, USA) diluted in PBS for 30 minutes at 37 degrees. After washing with PBST, the color development solution (Sangon, Shanghai, China) was prepared, 100 μL per well, and the cells were placed in the incubator for 5-30 minutes, and then 50 μL of stop solution (Sangon, Shanghai, China) was added, and the cells were placed in an ELISA reader (Thermo Fisher, MA, USA) for color development reading at 450 nm.

[0105] Figure 8 The above results show that ConA and the isolated ITPRIPL1 extracellular region purified protein (IT1-RBD) directly bind to the CD3 extracellular region purified protein in a concentration-dependent manner, and the binding intensity of IT1-RBD is greater than that of ConA. The above results prove that ConA and the isolated ITPRIPL1 extracellular region purified protein (IT1-RBD) directly bind to the CD3ε extracellular region purified protein, and the binding intensity of IT1-RBD is greater than that of ConA.

[0106] Example 5: The isolated ITPRIPL1-RBD protein can be used to bind to CD3ε protein on the cell surface and transmit inhibitory signals into T cells

[0107] 1. Construction of HCT116-ITPRIPL1 and HCT116-CD3ε stable cell lines

[0108] The constructed full-length ITPRIPL1-Flag plasmid, CD3ε-HA plasmid and empty pcDNA3.1 plasmid were transfected into HCT116 cells (ATCC, VA, USA), respectively, and cultured in an incubator for 24-48 hours. 1000 μg / ml of Geneticin (G418) (Gibco, CA, USA) was added for screening. After 10-14 days, when all cells in the empty pcDNA3.1 plasmid transfection group died, HCT116-ITPRIPL1 and HCT116-CD3ε stable transfected cells were obtained.

[0109] 2. Flow cytometry demonstrated that the purified protein fragment of the extracellular region of ITPRIPL1 bound to Jurkat cells that highly expressed CD3.

[0110] The cultured Jurkat cells (ATCC, VA, USA) were counted, the cell number was adjusted to 2x105 per milliliter, and 200 microliters were added to 6 1.5ml EP tubes (Axygen, CA, USA). 0.1 microgram, 0.2 microgram, 0.4 microgram, and 0.8 microgram ITPRIPL1-RBD-6x-His recombinant protein (IT1-6x-His protein) were added to 4 of the EP tubes to make the concentrations 0.5 micrograms per milliliter, 1 microgram per milliliter, 2 micrograms per milliliter, and 4 micrograms per milliliter. All EP tubes were placed in a cell culture incubator and allowed to stand for 30 minutes, and then the EP tubes were removed and the supernatant was discarded after centrifugation at 400rcf for 5 minutes. The cells were resuspended and washed with 500 microliters of cell staining buffer (Invitrogen, CA, USA), and the supernatant was discarded again after centrifugation at 400rcf for 5 minutes and the washing was repeated. Dilute 6x-His-FITC antibody (Abcam, MA, USA) with cell staining buffer at 1:500. Except for the negative control, add 200 μl of antibody diluent to each EP tube and incubate on a shaker at 40 rpm for 30 minutes at room temperature. Then take out the EP tube, centrifuge at 400 rcf for 5 minutes and discard the supernatant. Resuspend and wash the cells with 1000 μl of cell staining buffer, centrifuge at 400 rcf for 5 minutes and discard the supernatant again and repeat the washing. After washing, add 300 μl of cell staining buffer to each EP tube and resuspend, transfer to a flow tube (Falcon, NY, USA), and perform on-machine analysis (Miltenyi Biotec, Cologne, Germany).

[0111] Fig. 9 (a) is the threshold setting for not classifying dead cells. Fig. 9 (b) reflects the binding of Jurkat cells to different concentrations of purified protein fragments of the extracellular region of ITPRIPL1. Fig.10 Then Fig. 9The above results show that the purified protein fragment of ITPRIPL1 extracellular domain can bind to Jurkat cells that highly express CD3.

[0112] 3. Flow cytometry demonstrated that ITPRIPL1 protein bound to cells overexpressing CD3 with higher efficiency.

[0113] The cultured HCT116 wild-type cells (ATCC, VA, USA) and HCT116-CD3ε stable cells were digested and counted, and the cell number was adjusted to 2x105 per milliliter, and 200 microliters were added to 5 and 3 1.5ml EP tubes (Axygen, CA, USA). 0.2 micrograms, 0.4 micrograms, and 0.8 micrograms of ITPRIPL1-RBD-6x-His recombinant protein were added to 3 EP tubes of HCT116 wild cells and 3 EP tubes of HCT116-CD3ε stable cells to make the concentrations of 1 microgram per milliliter, 2 micrograms per milliliter, and 4 micrograms per milliliter. All EP tubes were placed in a cell culture incubator and allowed to stand for 30 minutes, and then the EP tubes were removed and the supernatant was discarded after centrifugation at 400rcf for 5 minutes. The cells were resuspended and washed with 500 microliters of cell staining buffer (Invitrogen, CA, USA), and the supernatant was discarded again after centrifugation at 400rcf for 5 minutes and the washing was repeated. Dilute 6x-His-FITC antibody (Abcam, MA, USA) with cell staining buffer at 1:500. Except for the negative control, add 200 μl of antibody diluent to each EP tube and incubate on a shaker at 40 rpm for 30 minutes at room temperature. Then take out the EP tube, centrifuge at 400 rcf for 5 minutes and discard the supernatant. Resuspend and wash the cells with 1000 μl of cell staining buffer, centrifuge at 400 rcf for 5 minutes and discard the supernatant again and repeat the washing. After washing, add 300 μl of cell staining buffer to each EP tube and resuspend, transfer to a flow tube (Falcon, NY, USA), and perform on-machine analysis (Miltenyi Biotec, Cologne, Germany).

[0114] Fig.11 (a) is the threshold setting for not classifying dead cells. Fig.11 (b) reflects the binding of cells with different CD3ε expression levels to different concentrations of ITPRIPL1 recombinant protein. Fig.12 Then Fig.11 The above results show that the purified protein fragment of ITPRIPL1 extracellular domain can bind to HCT116 cells overexpressing CD3 but not to HCT116 cells not expressing CD3.

[0115] 4. Flow cytometry demonstrated that CD3 bound to cells overexpressing ITPRIPL1 with higher efficiency.

[0116] The cultured HCT116 wild-type cells (ATCC, VA, USA) and HCT116-ITPRIPL1 stable cells were digested and counted, and the cell number was adjusted to 2x105 per milliliter, and 200 microliters were added to 3 and 1 1.5ml EP tubes (Axygen, CA, USA). 0.4 micrograms of CD3E-human Fc protein (Sino-Bio, Beijing, China) were added to 1 EP tube of HCT116 wild cells and 1 EP tube of HCT116-ITPRIPL1 stable cells to make the concentration 2 micrograms per milliliter. All EP tubes were placed in a cell culture incubator and allowed to stand for 30 minutes, and then the EP tubes were removed and the supernatant was discarded after centrifugation at 400rcf for 5 minutes. The washed cells were resuspended with 500 microliters of cell staining buffer (Invitrogen, CA, USA), and the supernatant was discarded again after centrifugation at 400rcf for 5 minutes and the washing was repeated. Anti-human IgG Alexa Fluor 647 antibody (Invitrogen, CA, USA) was diluted 1:1000 with cell staining buffer. Except for the negative control, 200 μL of antibody diluent was added to each EP tube and incubated at 40 rpm on a shaker at room temperature for 30 minutes. Then the EP tube was removed and the supernatant was discarded after centrifugation at 400 rcf for 5 minutes. The cells were resuspended and washed with 1000 μL of cell staining buffer, and the supernatant was discarded again after centrifugation at 400 rcf for 5 minutes and the washing was repeated. After washing, 300 μL of cell staining buffer was added to each EP tube and resuspended, transferred to a flow tube (Falcon, NY, USA), and analyzed on a flow cytometer (Miltenyi Biotec, Cologne, Germany).

[0117] Fig.13 (a) is the threshold setting for not classifying dead cells. Fig.13 (b) reflects the binding of cells with different ITPRIPL1 expression levels to CD3ε protein. Fig.14 They are Fig.13 The specific staining and protein binding conditions under each condition in (b) above indicate that CD3ε can bind to HCT116 cells expressing ITPRIPL1, and can bind more strongly to HCT116 cells overexpressing ITPRIPL1.

[0118] 5. Luciferin reporter experiments demonstrated that the purified protein fragment of the extracellular region of ITPRIPL1 inhibited the NFKB proliferation signal of Jurkat-dual cells activated by ConA.

[0119] The cultured Jurkat-dual cells (Invivogen, CA, USA) were counted, centrifuged at 1000rpm x5 minutes, and resuspended in IMDM medium (Gibco, CA, USA) without antibiotics to adjust the cell number to 2x106 per ml, and 200 μl of cells were added to each well of a transparent 96-well plate (Thermo Fisher, MA, USA). 0.2 μg, 0.4 μg, and 0.8 μg of ITPRIPL1-6x-His recombinant protein were added to each well to make the concentrations of 1 μg per ml, 2 μg per ml, and 4 μg per ml, respectively. After being placed in a cell culture incubator for two hours, 10 μg per ml of concanavalin A (ConA) (Aladdin, Shanghai, China) was added to each well and placed in a cell culture incubator for 18-24 hours. After the reaction was completed, an opaque 96-well plate (costar, ME, USA) was taken, and 50 μl of Quanti-luc reagent (Invivogen, CA, USA) and 20 μl of reaction mixture were added to each well. After adding and mixing, the signal was immediately detected using a multifunctional microplate reader (Thermo Fisher, MA, USA).

[0120] like Fig.15 As shown, the changes in NFKB signal with the concentration of ITPRIPL1 protein under the condition of 10 μg / ml ConA activation. The above results show that the purified recombinant protein of ITPRIPL1-RBD can inhibit the NFKB proliferation signal of Jurkat-dual cells activated by ConA in a concentration-dependent manner.

[0121] 6. Luciferase reporter experiments demonstrated that the purified protein fragment of the extracellular domain of ITPRIPL1 immobilized on the surface of the microspheres inhibited the NFKB proliferation signal of Jurkat-dual cells activated by ConA.

[0122] Protein G magnetic microspheres (Thermo Fisher, MA, USA) and His antibodies (Abcam, MA, USA) were placed in 4 EP tubes (Axygen, CA, USA) and placed in a DNA mixer (Xinzhi, Ningbo, China) and rotated at the lowest speed for 1 hour at room temperature. 0.2 μg, 0.4 μg, and 0.8 μg of ITPRIPL1-6x-His recombinant protein were added to 3 of the EP tubes and rotated at the lowest speed for 1 hour at room temperature again. The cultured Jurkat-dual cells (Invivogen, CA, USA) were counted, centrifuged at 1000 rpm x 5 minutes, and resuspended in IMDM medium (Gibco, CA, USA) without antibiotics to adjust the cell number to 2x106 per milliliter. 200 μl of cells were added to each well of a transparent 96-well plate (Thermo Fisher, MA, USA). The contents of each EP tube were added to each well to make the coating protein concentration 1 μg per milliliter, 2 μg per milliliter, and 4 μg per milliliter. After two hours of reaction in a cell culture incubator, 50 μg / mL concanavalin A (ConA) (Aladdin, Shanghai, China) was added to each well and placed in a cell culture incubator for 18-24 hours. After the reaction was completed, an opaque 96-well plate (costar, ME, USA) was taken, 50 μL of Quanti-luc reagent (Invivogen, CA, USA) and 20 μL of reaction mixture were added to each well, and the signal was immediately detected using a multifunctional microplate reader (Thermo Fisher, MA, USA) after mixing.

[0123] like Fig.16 As shown in the figure, under the condition of 50 μg / ml ConA activation, the NFKB signal changes with the concentration of ITPRIPL1 protein coated on the microspheres. The above results show that the ITPRIPL1-RBD purified recombinant protein immobilized on the surface of the microspheres can inhibit the NFKB proliferation signal of Jurkat-dual cells activated by ConA in a concentration-dependent manner.

[0124] 7. Detect the expression level of ITPRIPL1 in different types of tumor cells

[0125] Since the extracellular region of ITPRIPL1 has the function of inhibiting immune cells (such as T cells), tumor cells may express ITPRIPL1 to escape the surveillance and killing of the immune system. If multiple tumor cells abnormally express ITPRIPL1, it indicates that ITPRIPL1 may promote the occurrence and development of tumors (including immune escape). The present invention reveals that ITPRIPL1 has abnormal expression in cell lines from different types of tumors. The specific experimental steps are: count each cultured cell line, take 2x106 cells to a 15ml centrifuge tube, centrifuge at 800rpm x4 minutes, discard the supernatant, resuspend and wash with PBS, centrifuge at 800rpm x4 minutes, and repeat PBS resuspending and washing. After centrifugation, discard the supernatant, prepare RIPA lysis buffer and protease, phosphatase, and PMSF at 1:100, add 120 microliters of mixed lysis buffer to each tube of cells, and transfer to an EP tube. Each EP tube was frozen and thawed three times on liquid nitrogen-ice, and centrifuged at 12000rpm for 15 minutes at 4 degrees Celsius after the last thawing. After centrifugation, the supernatant was taken and each cell sample was prepared with a ratio of 4:1 of supernatant after centrifugation: 5x loading buffer and placed in a 100°C metal bath for 10 minutes for denaturation. After denaturation, the endogenous expression of ITPRIPL1 in each tumor cell line was determined by gel electrophoresis and immunoblot analysis with GAPDH as an internal reference.

[0126] Fig.17 The expression of ITPRIPL1 after adjusting with GAPDH as internal reference in immunoblotting. Fig.17 As shown, immunoblotting experiments detected the expression of ITPRIPL1 protein in tumor cell lines, including LoVo colorectal cancer, Raji lymphoma, RL lymphoma, MDA-MB-231 breast cancer, HCT116 colorectal cancer, A549 lung cancer, HL60, Jurkat lymphoma, H1299 lung cancer, and A375 melanoma cells, all of which had high levels of expression. Although the inventors did not detect the expression of ITPRIPL1 in all types of tumor cells, judging from the proportion of ITPRIPL1 expressed in the tumor cells that have been detected (10 / 11, more than 90%), ITPRIPL1 may have multiple types of fairly extensive expression in malignant tumors.

[0127] Accordingly, the results extracted from the Protein Atlas database based on high-throughput mRNA expression profiling suggest that ITPRIPL1 may have cases with significantly elevated expression in a variety of tumors. No reports on the function of ITPRIPL1 have been seen in the past. Therefore, before the disclosure of the present invention, technicians in this field could not predict any function of ITPRIPL1 in tumor development and immune escape. The present invention discloses experimental data such as abnormally elevated expression of ITPRIPL1 tumor cell protein levels, and the binding of the ITPRIPL1 extracellular region to CD3ε and causing T cell inhibition, which reveals for the first time the important value of ITPRIPL1 as a target for tumor immunotherapy.

[0128] like Fig.18 As shown in Figure 1, according to the mRNA expression profile data collected by the Protein Atlas website, ITPRIPL1 may be mainly expressed in testis and T cells in normal tissues or cells. It is worth noting that the expression of mRNA cannot directly represent the expression at the protein level, and in general, the re-analysis of expression profile data still needs to be verified by low-throughput biological experiments (such as protein gel electrophoresis immunoblotting analysis) to obtain reliable conclusions.

[0129] Example 6: Use of isolated ITPRIPL1-RBD as an immunogen to prepare neutralizing antibodies

[0130] 1. Preparation of mouse polyclonal antibodies and polyclonal antibodies using ITPRIPL1-RBD as an immunogen

[0131] The human ITPRIPL1-RBD recombinant protein was used as an immunogen. After the purity and biological activity of the sample were verified in the above examples, C57BL / 6 mice were immunized. Multiple immunizations were performed to enhance the effect: (1) The first immunization was 50 μg of antigen per mouse, and Freund's complete adjuvant was added for subcutaneous injection at multiple points, with an interval of 3 weeks; (2) The second immunization was the same as above, with Freund's incomplete adjuvant, with an interval of 3 weeks; (3) The third immunization was the same as above, without adjuvant, and intraperitoneal injection was performed at an interval of 3 weeks; (4) The booster immunization was 50 μg, intraperitoneal injection. Blood was collected 3 days after the last injection to measure its titer. After the immune effect was detected to meet the requirements, blood was collected multiple times in an accumulative manner, polyclonal antibodies were separated, and polyclonal antibodies were purified. The specific experimental steps included: (1) Prepare a protein G sepharose CL-4B affinity column. Prepare 10 mL of protein G sepharose CL-4B filler, mix equal volumes of filler and TBS buffer solution in a vacuum bottle, and stir. Vacuum for 15 minutes to remove bubbles in the filler. Slowly add protein Gsepharose CL-4B filler to the glass column, use a pump to control the filling speed to 1mL / min-2mL / min, avoid column drying, and balance the column with 10 times the bed volume and pre-cooled TBS buffer solution. (2) Prepare polyclonal antibodies. Slowly thaw the polyclonal antibodies in ice water or a 4°C refrigerator to avoid protein aggregation. Aggregates that appear during protein thawing can be dissolved by preheating at 37°C. Add solid sodium azide to a concentration of 0.05%, centrifuge at 4°C, 15,000×g for 5 minutes, remove the clarified polyclonal antibodies and filter through a filter to remove excess lipids. (3) Affinity chromatography. Dilute the antibody with TBS buffer solution at a ratio of 1:5, and then filter through a filter. Load the polyclonal antibody onto the column at a rate of 0.5mL per minute. To ensure the binding of the polyclonal antibody to the filler, load the column twice in a row and retain the load effluent. Wash the column with TBS buffer solution until Aλ280nm<0.008, then add Ph 2.7 elution buffer solution and elute at a rate of 0.5mL / min until all proteins flow down. Collect the eluate in 1.5mL EP tubes to which 100μL neutralization buffer solution has been added. After mixing, check the pH of the eluate with pH test paper. If the pH is lower than 7, adjust it to about pH7.4 with neutralization buffer to prevent denaturation of the antibody. Add 10mL, pH1.9 elution buffer solution to the column and collect the eluate as described above until Aλ280nm<0.008. Determine the protein content in each tube using a spectrophotometer.

[0132] 2. Enzyme-linked immunosorbent assay (ELISA) demonstrated that the polyclonal antibody against ITPRIPL1-RBD as an immunogen could bind to cells expressing ITPRIPL1

[0133] ELISA plates (costar, ME, USA) were used. First, B16 cells (ATCC, VA, USA) that do not express ITPRIPL1, LoVo cells (ATCC, VA, USA) that express ITPRIPL1 to a moderate degree, and HCT116-ITPRIPL1 stable cells were trypsinized and counted, and the cell number was adjusted to 2x106 per ml, 100 μl of cells were plated per well, and coated overnight at 4°C. After washing with PBST, 100 μl of 5% skim milk powder (Shanghai, China) dissolved in PBS was used for blocking, and the cells were blocked at 37 degrees incubator for 90 minutes. After washing with PBST, the polyclonal antibody with a total IgG concentration of 10 mg per ml was diluted in a gradient of 1:1000 / 1:500 / 1:250 / 1:125, incubated with the plated cells, and combined at 37 degrees incubator for 60 minutes. After washing with PBST, the cells were incubated with specific anti-mouse Fc antibody (Conson, Shanghai, China) diluted in PBS for 30 minutes at 37°C. After washing with PBST, colorimetric solution (Sangon, Shanghai, China) was prepared, 100 μl per well, and the cells were placed in an incubator for 5-30 minutes, and then 50 μl of stop solution (Sangon, Shanghai, China) was added, and the cells were placed in an ELISA reader (Thermo Fisher, MA, USA) for colorimetric reading at 450 nm.

[0134] Fig.19 (a) shows the changes in the binding rate of B16 cells to polyclonal antibodies of different concentrations. Fig.19 (b) shows the changes in the binding rate of LoVo cells to different concentrations of polyclonal antibodies. Fig.19 (c) shows the change in binding rate between HCT116-ITPRIPL1 stable cells and polyclonal antibodies at different concentrations. This experiment shows that with the increase in IgG concentration in the polyclonal antibody, there is no obvious change trend in the binding rate between B16 cells and polyclonal antibodies, the binding rate between LoVo cells and polyclonal antibodies increases in a certain degree of concentration-dependent growth, and the binding rate between HCT116-ITPRIPL1 stable cells and polyclonal antibodies increases in a significant concentration-dependent manner. The above results prove that polyclonal antibodies can bind to cells expressing ITPRIPL1.

[0135] 3. Enzyme-linked immunosorbent assay (ELISA) demonstrated that polyclonal antibodies could block the binding of ITPRIPL1 to CD3ε.

[0136] ELISA plates (costar, ME, USA) were used. First, 0.1 μg of CD3ε protein fragment (Sino Biological, Beijing, China) was dissolved in 100 μl of ELISA coating solution (Solarbio, Beijing, China) to coat the plate. The CD3ε (Met 1-Asp117) protein was labeled with hFc. The negative control was coated with 100 μl of coating solution without protein. Coating was carried out overnight at 4°C. After washing with PBST, the plate was blocked with 100 μl of 5% skim milk powder (Sangong, Shanghai, China) dissolved in PBS, and blocked in an incubator at 37 degrees for 90 minutes. After washing with PBST, 2 μg / ml of ITPRIPL1-RBD-6x-His protein was mixed with 1:1000 / 1:500 / 1:250 / 1:125 of polyclonal antibodies with a total IgG concentration of 10 mg / ml, and then co-incubated and bound, and bound in an incubator at 37 degrees for 60 minutes. After washing with PBST, the cells were incubated with specific anti-6x-His tag horseradish peroxidase antibody (Abcam, MA, USA) diluted in PBS for 30 minutes at 37°C. After washing with PBST, colorimetric solution (Sangon, Shanghai, China) was prepared, 100 μL per well, and the cells were placed in an incubator for 5-30 minutes, and then 50 μL of stop solution (Sangon, Shanghai, China) was added, and the cells were placed in an ELISA reader (Thermo Fisher, MA, USA) for colorimetric reading at 450 nm.

[0137] like Fig. 20 As shown, the experiment showed that as the IgG concentration in the polyclonal antibody increased, the binding rate of CD3ε to ITPRIPL1-RBD protein gradually decreased. The above results prove that the polyclonal antibody can block the binding between ITPRIPL1 and CD3ε.

[0138] 4. Flow cytometry demonstrated that polyclonal antibodies could block the binding of ITPRIPL1 to cells overexpressing CD3ε.

[0139] After digestion, count the HCT116-CD3ε stable cells, adjust the cell number to 2x105 per milliliter, and add 200 microliters to 8 1.5ml EP tubes (Axygen, CA, USA). Add 0.8 micrograms of IT1-RBD protein to each EP tube to make its concentration 4 micrograms per milliliter. Add 1:1000 / 1:500 / 1:250 / 1:125 / 1:67.5 dilutions of polyclonal antibodies with a total IgG concentration of 10 mg per milliliter to five of the EP tubes, and place them in a cell culture incubator for 30 minutes. Then remove the EP tube, centrifuge at 400rcf for 5 minutes, and discard the supernatant. Resuspend and wash the cells with 500 microliters of cell staining buffer (Invitrogen, CA, USA), centrifuge at 400rcf for 5 minutes, and discard the supernatant again and repeat the wash. Dilute 6x-His FITC antibody (Abcam, MA, USA) with cell staining buffer at 1:500. Except for the negative control, add 200 μl of antibody diluent to each EP tube and incubate on a shaker at 40 rpm for 30 minutes at room temperature. Remove the EP tube, centrifuge at 400 rcf for 5 minutes and discard the supernatant. Resuspend and wash the cells with 1000 μl of cell staining buffer, centrifuge at 400 rcf for 5 minutes and discard the supernatant again and repeat the wash. After washing, add 300 μl of cell staining buffer to each EP tube and resuspend, transfer to a flow tube (Falcon, NY, USA) and perform on-machine analysis (Miltenyi Biotec, Cologne, Germany).

[0140] Fig.21 (a) is the threshold setting for not classifying dead cells. Fig.21 (b) reflects the changes in the binding between ITPRIPL1 and CD3ε when the concentration of polyclonal antibodies changes. Fig. 22 Then Fig.21 The above results indicate that the polyclonal antibody can block the binding of ITPRIPL1 to cells overexpressing CD3ε.

[0141] Example 7: Regulating the activation of proliferation signaling pathways in T cell-derived cell lines by regulating the binding of ITPRIPL1-RBD and CD3 extracellular region

[0142] Since previous studies have shown that the binding of CD3ε may cause changes in T cell proliferation and function, and since T cells are primary cells, it is not conducive to intervention and detection. The most widely used model for such studies is Jurkat cells, which are cell lines derived from T cells, and NF-KB signal transduction is a widely used detection indicator that reflects the degree of activation of Jurkat or T cells. Therefore, we constructed a Jurkat-NFKB reporter cell line (firefly luciferase downstream of the NF-KB promoter was transduced into Jurkat cells through lentivirus, and it was detected that it could be activated by concanavalin A) to detect the effect of ITPRIPL1 on the functional state of co-cultured T cells when expressed in tumor cells.

[0143] First, luciferase reporter experiments demonstrated that HCT116 cells overexpressing ITPRIPL1 could further reduce the NFKB proliferation signal in Jurkat-dual cells, such as Fig.23 As shown. The cultured Jurkat-dual cells were counted, centrifuged at 1000rpm x5 minutes, and resuspended in IMDM medium without antibiotics to adjust the cell number to 2x106 per milliliter. 200 microliters of cells were added to each well of the transparent 96-well plate. HCT116 cells and HCT116-ITPRIPL1 stable cells were trypsinized and counted, and the cell number was adjusted to 2x106 per milliliter. 20 microliters were added to each and mixed with the corresponding Jurkat-dual cells. Place in a cell culture incubator and co-culture for 18-24 hours. After the reaction is completed, take an opaque 96-well plate, add 50 microliters of Quanti-luc reagent and 20 microliters of reaction mixture to each well, add and mix well, and immediately detect the signal with a multifunctional microplate reader. The above figure shows that HCT116 cells expressing ITPRIPL1 can inhibit the NFKB proliferation signal of Jurkat-dual cells, while HCT116 cells overexpressing ITPRIPL1 can further reduce the NFKB proliferation signal. The above results indicate that HCT116 cells overexpressing ITPRIPL1 can further reduce the NFKB proliferation signal of Jurkat-dual cells.

[0144] Furthermore, luciferase reporter experiments demonstrated that CD3ε protein could block the inhibition of NFKB proliferation signaling in Jurkat-dual cells by ITPRIPL1 protein. Fig.24As shown. The cultured Jurkat-dual cells were counted, centrifuged at 1000rpm x5 minutes, and resuspended in IMDM medium without antibiotics to adjust the cell number to 2x106 per milliliter. 200 microliters of cells were added to each well of the transparent 96-well plate. 2 micrograms per milliliter of ITPRIPL1 protein and 0 micrograms per milliliter, 1 microgram per milliliter, 2 micrograms per milliliter, and 4 micrograms per milliliter of CD3ε protein mixtures were added to each well. After being placed in a cell culture incubator for two hours, 50 micrograms per milliliter of concanavalin A (ConA) was added to each well and placed in a cell culture incubator for 18-24 hours. After the reaction was completed, an opaque 96-well plate was taken, 50 microliters of Quanti-luc reagent and 20 microliters of reaction mixture were added to each well, and the signal was immediately detected using a multifunctional microplate reader after mixing. The above figure reflects the changes in the NFKB signal of Jurkat-dual cells under the conditions of 50 micrograms per milliliter ConA activation, the addition of 2 micrograms per milliliter of ITPRIPL1 protein and different concentrations of CD3ε protein. The above results indicate that the inhibition of NFKB proliferation signal of ConA-activated Jurkat-dual cells by ITPRIPL1 protein can be blocked by CD3ε protein in a concentration-dependent manner, indicating that the inhibitory effect of ITPRIPL1 is produced through CD3ε.

[0145] Example 8: ITPRIPL1-RBD recombinant protein can reduce the killing of human peripheral blood mononuclear cells (PBMC) on kidney-derived H3K293 cells

[0146] Flow cytometry was used to demonstrate that ITPRIPL1-RBD recombinant protein can reduce the killing of human peripheral blood mononuclear cells (PBMC) on kidney-derived H3K293 cells. CD3 and CD28 antibodies (Invitrogen, CA, USA) were mixed and diluted with PBMC (ATCC, VA, USA) to a final concentration of 1 μg / ml to activate T cells and cultured overnight. The next day, PBMC and 293E (ATCC, VA, USA) cells were counted and the cell number was adjusted to 1x106 / ml, 100 μl of 293E cells and 100 μl of culture medium were added to the control group, and 100 μl of each of the two cells in the experimental group was added to a 96-well plate (Thermo Fisher, MA, USA). In the experimental group, 4 groups were added with 1, 2, 4, and 8 μg / ml of ITPRIPL1-RBD recombinant protein, respectively, and incubated in an incubator for 6 hours. Remove the 96-well plate, place the cells in each well in an EP tube (Axygen, CA, USA), centrifuge at 400 rcf for 5 minutes, and discard the supernatant. Resuspend and wash the cells with 500 μl of cell staining buffer (Invitrogen, CA, USA), repeat centrifugation and washing. Dilute CD45-APC antibody (Invitrogen, CA, USA) at 1:20 with cell staining buffer, add 200 μl of the mixture to each EP tube and resuspend, incubate at room temperature for 30 minutes with slow shaking. Centrifuge at 400 rcf for 5 minutes and discard the supernatant, resuspend and wash the cells with 1 ml of binding buffer (Mei Lun, Shanghai, China); repeat centrifugation and washing. The unstained group without PBMC, the double-stained group without PBMC, the unstained group with PBMC, the group with PBMC single-stained with Annexin V-FITC, the group with PBMC single-stained with PI, the group with PBMC double-stained, and the double-stained groups with ITPRIPL1 protein were set up. According to the conditions, 100 μl of binding buffer, 5 μl of Annexin V-FITC (Meilun, Shanghai, China) and 10 μl of PI (Meilun, Shanghai, China) were added respectively, incubated at room temperature with slow shaking for 15 min, and then 400 μl of binding buffer was added to each group. The cells were transferred to flow tubes (Falcon, NY, USA) and loaded into an instrument (Miltenyi Biotec, Cologne, Germany).

[0147] Fig.25 (a) and (b) show the classification of 293E cells based on CD45. Fig.25 (c) is the relative killing activity of PBMC calculated based on the apoptosis data of each group under different ITPRIPL1 protein concentrations. Fig.26 for Fig.25 The specific apoptosis staining conditions under each condition in (c). The above results show that ITPRIPL1-RBD recombinant protein can reduce the killing of human peripheral blood mononuclear cells (PBMC) on kidney-derived H3K293 cells.

[0148] Example 9: Knocking out ITPRIPL1 expressed in tumor cells by gene editing can significantly increase the killing of tumor cells by human peripheral blood mononuclear cells

[0149] 1. Construct a CRISPR / Cas9 gene editing system, namely a lentivirus containing a puromycin-resistant sgRNA that specifically cuts ITPRIPL1.

[0150] The overall experimental process: First, synthesize the single-stranded DNA oligo of the gRNA sequence, then anneal and pair to produce a double-stranded DNA oligo, and then directly connect it to the CRISPR / Cas9 vector after restriction digestion through the restriction sites contained at both ends; transfer the ligation product into the prepared bacterial competent cells, and send the grown monoclonal colonies to the sequencing company for sequencing and identification. The correct clone is the successfully constructed CRISPR / Cas9 vector. For the target gene sequence of the target gene, use the gRNA sequence design principles provided on the public website to design multiple target site sequences, as shown in SEQ ID NOs: 11-13. According to the gene sequence, three pairs of gRNA oligo single-stranded DNA were designed and synthesized, and the oligo sequences were shown in SEQ ID NOs: 14-19, wherein SEQ ID NOs: 14, 15 are the gRNA oligo single-stranded DNA sequences corresponding to the target sequence SEQ ID NO: 11; SEQ ID NOs: 16, 17 are the gRNA oligo single-stranded DNA sequences corresponding to the target sequence SEQ ID NO: 12; SEQ ID NOs: 18, 19 are the gRNA oligo single-stranded DNA sequences corresponding to the target sequence SEQ ID NO: 13. The oligo single-stranded DNA was annealed into double strands, and the double-stranded gRNA oligo was inserted into the CRISPR / Cas9 vector, respectively, to construct the CRISPR / Cas9 recombinant plasmid, and transformed into the competent cell Stbl3. The construction of the vector includes the following specific steps:

[0151] 1) Annealing of gRNA: Dilute the primers with sterile TE buffer to a final concentration of 100 μMol. Pipette 10 μl of upstream and downstream primers respectively, mix them and pipette evenly into the PCR tube for annealing. After completion, place them on ice for a few minutes and then connect directly or store them in a freezer at -20°C.

[0152] 2) Enzyme digestion and recovery of CRISPR / Cas9 vector: The enzyme digestion system is as follows: CRISPR / Cas9 vector 5μg; 10*Buffer 5μl; BsmBI 4μl; ddH2O to 50μl. Enzyme digestion at 37℃ for about 30min. During this period, 0.8% agarose gel can be prepared, and nucleic acid electrophoresis can be performed after the enzyme digestion is completed. After the electrophoresis is completed, cut the gel strip containing the target fragment. Use a balance to weigh the total weight and subtract the weight of the empty tube to calculate the weight of the gel. Calculate the volume of the gel based on 100mg is approximately 100μl, and add 3 times the volume of QG buffer to place in a 50℃ water bath to completely melt the gel. Shake the EP tube appropriately during this period to accelerate the dissolution of the gel. After the gel is completely melted, add isopropanol equal to the volume of the gel and mix well. Transfer all the above liquids to the filter column and centrifuge at 13000rpm for 30s. Discard the liquid in the tube, add 750μl of PE buffer to the column, and centrifuge for 1min. Discard the liquid in the tube and empty it again for 1 minute. Replace with a new 1.5 ml EP tube, add 50 μl of EB buffer to the column, centrifuge for 1 minute, and the recovered vector is in the centrifuge tube.

[0153] 3) Ligation of CRISPR / Cas9 vector and primers. The ligation system is as follows: 3 μl (50 ng) of recovery vector; 1 μl (0.5 μM) of oligo primer; 1.5 μl of T4 DNA ligase buffer; 1 μl of T4 DNA ligase; 15 μl of ddH2O. Incubate in a 25°C water bath for 30 min.

[0154] 4) Transformation: Place the competent cells on ice and wait for them to thaw naturally. Add all the ligation products to the competent cells, place them on ice for 20 minutes, and then heat shock them in a 42°C water bath for 90 seconds. Then quickly place them on ice for 2-3 minutes. Add 1000μl of LB culture medium without antibiotics and culture them at 37°C, 150rpm and shake for 45 minutes. Centrifuge at 3000rpm for 2 minutes, discard about 850μl of supernatant, blow and disperse the bacterial liquid at the bottom of the tube, add it to the culture dish containing the corresponding resistance, spread it evenly with a sterilized applicator, and invert it in a 37°C constant temperature incubator for overnight culture.

[0155] 5) Preparation of recombinant plasmid: Pick several single colonies and perform small-scale shaking culture.

[0156] 6) Sequencing to identify positive clones. After comparison, the inserted fragment sequence in the recombinant clone is completely consistent with the designed oligo sequence, so the vector is successfully constructed.

[0157] 2. Use the CRISPR / Cas9 gene editing system to perform gene editing and construct the HCT116-ITPRIPL1 knockout cell line.

[0158] HCT116 cells (ATCC, VA, USA) were plated in 24-well plates (Corning, NY, USA) at an appropriate density (grown to a density of about 30-40% on the second day), digested and counted the next day, and first infected with GFP control lentivirus (Jiman, Shanghai, China) in a gradient of quantity, and the medium was changed after 48 hours. GFP fluorescence was observed under a microscope after 72 hours to determine the optimal virus-cell infection ratio to explore the MOI value. After determining the MOI value, the plate was re-plated, and HCT116 cells were infected with a Cas9 system lentivirus containing blasticidin resistance (Jiman, Shanghai, China) at an MOI value, and the medium was changed after 48 hours. After 72 hours, a concentration gradient of blasticidin (Invivogen, CA, USA) was added to screen for 10-14 days, and the resulting cell line was finally screened, that is, HCT116 cells containing the Cas9 system. HCT116 cells containing the Cas9 system were plated and counted in a 24-well plate, and infected with a lentivirus containing a puromycin-resistant sgRNA that specifically cuts ITPRIPL1 at a certain MOI value. The medium was changed after 48 hours, and after 72 hours, a concentration gradient of puromycin (Invivogen, CA, USA) was introduced for screening for 10-14 days to obtain the HCT116-ITPRIPL1 knockout cell line.

[0159] 3. Flow cytometry demonstrated that knocking down ITPRIPL1 expressed in tumor cells could significantly increase the killing of tumor cells by human peripheral blood monocytes.

[0160] CD3 and CD28 antibodies (Invitrogen, CA, USA) were mixed and diluted with PBMC (ATCC, VA, USA) to a final concentration of 1 μg per ml to activate T cells and cultured overnight. The next day, PBMC and HCT116 wild-type (ATCC, VA, USA) / ITPRIPL1 overexpression / ITPRIPL1 knockout cells were counted and the cell number was adjusted to 1x106 per ml, 100 μl of tumor cells and 100 μl of culture medium were added to the control group, and 100 μl of tumor cells and PBMC were added to a 96-well plate (Thermo Fisher, MA, USA) in the experimental group and incubated in an incubator for 6 hours. The 96-well plate was removed, rinsed with PBS (Mei Lun, Dalian, China), and then digested with EDTA-free trypsin (Biyuntian, Shanghai, China), placed in an EP tube (Axygen, CA, USA), centrifuged at 400 rcf for 5 minutes, and the supernatant was discarded. Resuspend the washed cells with 500 μL of cell staining buffer (Invitrogen, CA, USA), repeat centrifugation and washing. Dilute CD45-APC antibody (Invitrogen, CA, USA) with cell staining buffer at 1:20, add 200 μL of the mixture to each EP tube and resuspend, incubate at room temperature for 30 minutes with slow shaking. Centrifuge at 400 rcf for 5 minutes, discard the supernatant, resuspend and wash the cells with 1 ml of binding buffer (Mei Lun, Dalian, China); repeat centrifugation and washing. The unstained group without PBMC, the double-stained group without PBMC, the unstained group with PBMC, the group with PBMC single-stained with Annexin V-FITC, the group with PBMC single-stained with PI, the group with PBMC double-stained, and the double-stained groups with IT1 protein were set up. According to the conditions, 100 μl of binding buffer, 5 μl of Annexin V-FITC (Mei Lun, Dalian, China) and 10 μl of PI (Mei Lun, Dalian, China) were added respectively, incubated at room temperature with slow shaking for 15 min, and then 400 μl of binding buffer was added to each group. The cells were transferred to flow tubes (Falcon, NY, USA) and loaded into a flow cytometer (Miltenyi Biotec, Cologne, Germany).

[0161] Fig. 27 (a) and (b) represent the classification of tumor cells based on CD45. Fig. 27 (c) is the relative killing activity of PBMC calculated based on the apoptosis data of each group under different ITPRIPL1 expression conditions. Fig.28 for Fig. 27 The above results show that ITPRIPL1 overexpression can reduce the killing of tumor cells by PBMC, while ITPRIPL1 knockout can promote the killing of tumor cells by PBMC.

[0162] Example 10: Antibodies prepared using ITPRIPL1-RBD protein as an immunogen can effectively promote immune cells to kill tumor cells

[0163] CD3 and CD28 antibodies (Invitrogen, CA, USA) were mixed and diluted with PBMC (ATCC, VA, USA) to a final concentration of 1 μg per ml to activate T cells and cultured overnight. The next day, PBMC and HCT116 cells (ATCC, VA, USA) were counted and the cell number was adjusted to 1x106 per ml, 100 μl of HCT116 cells and 100 μl of culture medium were added to the control group, and 100 μl of each of the two cells in the experimental group was added to a 96-well plate (Thermo Fisher, MA, USA). In the experimental group, 4 groups were added with 1:500 / 250 / 125 / 62.5 ITPRIPL1 polyclonal antibodies, and incubated in an incubator for 6 hours. Remove the 96-well plate, rinse with PBS (Mei Lun, Shanghai, China), digest the cells with EDTA-free trypsin (Biyuntian, Shanghai, China), place in an EP tube (Axygen, CA, USA), centrifuge at 400 rcf for 5 minutes, and discard the supernatant. Resuspend and wash the cells with 500 μl of cell staining buffer (Invitrogen, CA, USA), repeat centrifugation and washing. Dilute CD45-APC antibody (Invitrogen, CA, USA) with cell staining buffer at 1:20, add 200 μl of the mixture to each EP tube and resuspend, incubate at room temperature for 30 minutes with slow shaking. Centrifuge at 400 rcf for 5 minutes and discard the supernatant, resuspend and wash the cells with 1 ml of binding buffer (Mei Lun, Shanghai, China); repeat centrifugation and washing. The unstained group without PBMC, the double-stained group without PBMC, the unstained group with PBMC, the group with PBMC single-stained with Annexin V-FITC, the group with PBMC single-stained with PI, the group with PBMC double-stained, and the double-stained groups with ITPRIPL1 protein were set up. According to the conditions, 100 μl of binding buffer, 5 μl of Annexin V-FITC (Meilun, Shanghai, China) and 10 μl of PI (Meilun, Shanghai, China) were added respectively, incubated at room temperature with slow shaking for 15 min, and then 400 μl of binding buffer was added to each group, and the cells were transferred to flow tubes (Falcon, NY, USA) and loaded into a flow cytometer (Miltenyi Biotec, Cologne, Germany).

[0164] Fig.29 (a) and (b) show the classification of HCT116 cells based on CD45. Fig.29 (c) is the relative killing activity of PBMC calculated based on the apoptosis data of each group under different polyclonal antibody concentrations. Fig.30 for Fig.29The specific apoptosis staining conditions under each condition in (c). The above results indicate that ITPRIPL1 polyclonal antibody can promote the killing of tumor cells by PBMC.

[0165] Example 11: The binding ability of the ITPRIPL1-RBD2 sequence mutant to CD3E is reduced to a certain extent, and the binding ability of ITPRIPL1-RBD3 to CD3ε is significantly reduced

[0166] 1. Construction of HCT116-RBD2 and RBD3 sequence mutants

[0167] Based on the published sequence (NCBI reference sequence NM_001008949.3), DRMDLDTLARSRQLEKRMSEEMRLLEMEFEERKRAAEQRQKAENFWTGDTSSDQ (ITPRIP L1-RBD2, i.e., SEQ ID NO: 2) and MDLDTLARSRQLEKRMSEEMRLLEMEFEERKRAAEQRQKAEN (ITPRIPL1-RBD3, i.e., SEQID NO: 3) in the extracellular region (25-103 amino acids) were selected as two different target sequences, and specific ITPRIPL1 sequence mutants were synthesized, and pcDNA3.1 was used as the vector, in which the C-termini of the extracellular region, the transmembrane region and the extracellular region were fused to a Flag tag and green fluorescent protein (GFP), thereby generating ITPRIPL1 extracellular region, ITPRIPL1-RBD2, and ITPRIPL1-RBD3 plasmids containing a Flag tag and green fluorescent protein (GFP).

[0168] 2. Immunoprecipitation experiments showed that ITPRIPL1-RBD2 was the shortest sequence that bound to CD3E.

[0169] The pcDNA3.1 plasmids containing the extracellular region of ITPRIPL1 with a Flag tag, ITPRIPL1-RBD2, ITPRIPL1-RBD3 and HA-tagged CD3E were co-transfected into HCT116 cells (ATCC, VA, USA) and cultured in six-well plates (Corning, NY, USA) for 48-72 hours until the proteins were fully expressed. Then, the cells were lysed with 1:100 immunoprecipitation buffer (Thermo Fisher, MA, USA) and a combination of protease inhibitors, phosphatase inhibitors and PMSF (Conson, Shanghai, China). , China) mixed lysis buffer and scraped cells, a portion of the cell samples were centrifuged, mixed with sample buffer (Biyuntian, Shanghai, China) and denatured in a metal bath at 100 degrees Celsius to obtain input protein samples; the remaining cell samples were immunoprecipitated with HA tag-specific mouse antibody (Biolegend, CA, USA) or Flag tag-specific mouse antibody (CST, MA, USA), washed with PBS, mixed with sample buffer (Biyuntian, Shanghai, China) and denatured in a metal bath at 100 degrees Celsius to obtain immunoprecipitated protein samples. Then, 12.5% ​​PAGE gel (Yazyme, Shanghai, China) was prepared in a gel plate (Bio-Rad, CA, USA) according to the instructions, the prepared gel was placed in an electrophoresis tank (Bio-Rad, CA, USA), and the power supply (Bio-Rad, CA, USA) was connected to run the strip through the concentrated gel at a constant voltage of 80 volts and the separation gel at a constant voltage of 120 volts. When the bands run to the bottom of the separation gel, the membrane was transferred by wet transfer, and the membrane was transferred at a constant current of 350 mA for 90 minutes in a transfer tank (Bio-Rad, CA, USA). After the transfer was completed, the membrane was cut according to the mass size of ITPRIPL1 extracellular region, ITPRIPL1-RBD2, ITPRIPL1-RBD3 and CD3E-HA protein. The membrane was blocked with a rapid blocking solution (YaZyme, Shanghai, China) for ten minutes, and the corresponding bands of ITPRIPL1 extracellular region, ITPRIPL1-RBD2, ITPRIPL1-RBD3 and CD3E-HA were incubated with Flag tag-specific rabbit antibodies (Abcam, MA, USA) and HA tag-specific rabbit antibodies (CST, MA, USA) respectively, and the membrane was transferred overnight for four times. The next day, after washing with TBST, the sections were incubated with specific anti-rabbit secondary antibody (Conson, Shanghai, China) diluted in 5% skim milk powder (Sangon, Shanghai, China) dissolved in TBS for one hour at room temperature, washed with TBST, placed in mixed luminescent solution (Shenger, Shanghai, China) for one minute, and exposed under a gel imager (Bio-Rad, CA, USA).

[0170] Fig.31 (a) shows the content of different ITPRIPL1 sequence mutants and CD3ε in the input protein. Fig.31 (b) shows ITPRIPL1 mutants of different sequences that precipitate indirectly (due to binding to CD3ε), and directly precipitate CD3ε. Fig.31(c) shows the content of different ITPRIPL1 sequence mutants and CD3ε in the input protein. Fig.31 (d) shows CD3E indirectly precipitated (due to binding to mutants with different sequences of ITPRIPL1) and directly precipitated mutants with different sequences of ITPRIPL1. The above results show that CD3E and ITPRIPL1 remain bound in the presence of the extracellular region of ITPRIPL1 and RBD2 sequence mutants; while no obvious binding can be detected with the RBD3 sequence. It can be concluded that there is a positive correlation between the length or completeness of the ITPRIPL1 extracellular region and the ability to bind to CD3E.

[0171] Example 12: The isolated ITPRIPL1-RBD protein has the ability to bind to NRP2

[0172] 1. Enzyme-linked immunosorbent assay (ELISA) confirmed that the isolated ITPRIPL1 (IT1) extracellular domain fragment directly bound to the NRP2 extracellular domain in a concentration-dependent manner.

[0173] Use ELISA plates (costar, ME, USA). First, 0.03125 / 0.0625 / 0.125 / 0.25 / 0.5 / 1 / 2 μg / ml of ITPRIPL1-RBD recombinant protein was dissolved in 100 μl of ELISA coating solution (Solarbio, Beijing, China) to coat the plate. The negative control was coated with 100 μl of protein-free coating solution. Coat at four degrees overnight. After washing with PBST, block with 100 μl of 5% BSA (VWR, PA, USA) dissolved in PBS and block at 37 degrees incubator for 90 minutes. After washing with PBST, incubate with 1 μg / ml of NRP2 extracellular domain protein fragment (Sino-Bio, Beijing, China), which carries an hFc tag (N2-Fc), and bind for 60 minutes at 37 degrees incubator. After washing with PBST, the cells were incubated with specific anti-human Fc antibody (Abcam, MA, USA) diluted in PBS for 30 minutes at 37°C. After washing with PBST, the cells were developed with colorimetric solution (Sangon, Shanghai, China), 100 μl per well, incubated for 5-30 minutes, and then 50 μl of stop solution (Sangon, Shanghai, China) was added, and the cells were read at 450 nm using an ELISA reader (Thermo Fisher, MA, USA).

[0174] like Fig.32 As shown, the experiment shows that the isolated ITPRIPL1 extracellular region fragment directly binds to the NRP2 extracellular region in a concentration-dependent manner. The above results prove that the isolated ITPRIPL1 extracellular region purified protein (IT1-RBD) directly binds to the NRP2 extracellular region purified protein in a concentration-dependent manner.

[0175] 2. Flow cytometry demonstrated that NRP2 bound to cells overexpressing ITPRIPL1 with higher efficiency.

[0176] It was detected that HEK293 cells endogenously expressed a certain level of ITPRIPL1, and the expression level was further increased after stable expression. The cultured 293E wild-type cells (ATCC, VA, USA) and 293E-ITPRIPL1 stable cells were digested and counted, and the cell number was adjusted to 2x106 per ml, and 200 μl was added to each well of a 96-well plate (costar, ME, USA). 0 / 0.5 / 1 / 2 / 4 μg / ml of NRP2 protein (Sino Biological, Beijing, China) was added to each well of each experimental group. The 96-well plate was placed in a cell culture incubator and allowed to stand for 30 minutes, then removed and transferred to an EP tube (Axygen, CA, USA) and centrifuged at 400 rcf for 5 minutes, after which the supernatant was discarded. The cells were resuspended and washed with 500 μl of cell staining buffer (Invitrogen, CA, USA), centrifuged at 400 rcf for 5 minutes, and the supernatant was discarded again and washed repeatedly. Anti-human IgG Alexa Fluor 647 antibody (Invitrogen, CA, USA) was diluted 1:1000 with cell staining buffer. Except for the negative control, 200 μl of antibody diluent was added to each EP tube and incubated on a shaker at 40 rpm for 30 minutes at room temperature. Then the EP tube was removed and the supernatant was discarded after centrifugation at 400 rcf for 5 minutes. The cells were resuspended and washed with 1000 μl of cell staining buffer, and the supernatant was discarded again after centrifugation at 400 rcf for 5 minutes and the washing was repeated. After washing, 300 μl of cell staining buffer was added to each EP tube and resuspended, transferred to a flow tube (Falcon, NY, USA), and analyzed on a flow tube (Miltenyi Biotec, Cologne, Germany).

[0177] Fig.33 (a) is the threshold setting for not classifying dead cells. Fig.33 (b) reflects the binding of cells with different ITPRIPL1 expression levels to NRP2 protein. Fig.34 They are Fig.33 The above results show that NRP2 can bind to 293E cells with a certain expression of ITPRIPL1, and can bind more strongly to 293E cells that overexpress ITPRIPL1.

[0178] Example 13: The isolated ITPRIPL1-RBD protein has the ability to transmit inhibitory signals to differentiated THP1 macrophages expressing NRP2 protein

[0179] Luciferase reporter assay demonstrated that the isolated ITPRIPL1 extracellular domain purified protein (IT1-RBD) could inhibit the IFN proliferation signal of THP1-dual cells induced by PMA without activation.

[0180] The cultured THP1-dual cells (Invivogen, CA, USA) were counted, centrifuged at 1000rpmx5 minutes, and resuspended in RPMI-1640 medium (Gibco, CA, USA) without antibiotics to adjust the cell number to 2x106 per ml. 200 microliters of cells and 20 nanograms per milliliter of PMA reagent (Invivogen, CA, USA) were added to each well of a transparent 96-well plate (Thermo Fisher, MA, USA) for induction. After 3 hours of incubation in the incubator, PBS was washed and the medium was replaced. After 72 hours, the medium was replaced again and 0 / 1 / 2 / 4 / 8 micrograms per milliliter of the free, isolated extracellular region purified protein of ITPRIPL1 was added, respectively, and placed in a cell culture incubator for 18-24 hours. After the reaction was completed, an opaque 96-well plate was taken, and 50 microliters of Quanti-luc reagent (Invivogen, CA, USA) and 10 microliters of cell mixture were added to each well. After adding and mixing, the signal was immediately detected using a multifunctional microplate reader.

[0181] like Fig.35 As shown, the above results indicate that the free isolated ITPRIPL1 extracellular region purified protein (IT1-RBD) can inhibit the IFN proliferation signal of THP1-dual cells that have been differentiated by PMA-induced differentiation under non-activated conditions. From the above, it can be concluded that the isolated ITPRIPL1-RBD protein has the ability to transmit inhibitory signals to differentiated THP1 macrophages expressing NRP2 protein.

[0182] Example 14: The purified IT1-RBD-Fc protein has the function of inhibiting T cell signaling and killing

[0183] 1. Isolate and purify IT1-RBD-Fc protein.

[0184] Based on the publicly available sequence (NCBI reference sequence NM_001008949.3), the extracellular region (HPLMVSDRMDLDTLARSRQLEKRMSEEMRLLEMEFEERKRAAEQRQKAENFWTGDTSS DQLVLGKKDMGWPFQADGQEG) was selected as IT1-RBD1, of which DRMDLDTLARSRQLEKRMSEEMRLLEMEFEERKRAAEQRQKAENFWTGDTSSDQ was used as IT1-RBD2, and MDLDTLARSRQLEKRMSEEMRLLEMEFEERKRAAEQRQKAEN was used as IT1-RBD3, followed by a tandem Fc sequence without the CH1 region (PKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK), and pcDNA3.1 was used as the vector to construct the corresponding plasmid. After obtaining the plasmid, it was transfected into 293E cells (ATCC, VA, USA) using PEI reagent (Li Ji, Shanghai, China). After 120 hours, the cells were lysed on ice for 10 minutes using RIPA lysis buffer (Biyuntian, Shanghai, China) and a triple combination of protease inhibitors, phosphatase inhibitors, and PMSF (Kangchen, Shanghai, China). After centrifugation at 12000 rpm for 15 minutes, the supernatant was aspirated and shaken at 130 rpm at room temperature for 2 hours using 1:100 protein A magnetic beads (Tian Di Renhe, Changzhou, China). The mixed solution was aspirated into a filter column (Millipore, MA, USA) pre-equilibrated with equilibration solution (20 mM disodium hydrogen phosphate, 0.15 M sodium chloride, pH 7.0). After washing twice with the equilibration solution, the column was eluted with elution solution (0.1 M glycine, pH 3.0): neutralization solution (1 M Tris-HCl, pH 8.5) = 16:1. The eluted protein was purified IT1-RBD-Fc protein. The protein concentration was determined using a Nanodrop spectrophotometer and stored at -20°C.

[0185] 2. Luciferin reporter experiments demonstrated that the purified IT1-RBD1-Fc protein could inhibit the NFKB proliferation signal of Jurkat-dual cells under ConA activation and non-activation conditions.

[0186] The cultured Jurkat-dual cells (Invivogen, CA, USA) were counted, centrifuged at 1000rpmx5 minutes, and resuspended in IMDM medium (Gibco, CA, USA) without antibiotics to adjust the cell number to 2x106 per ml, and 200 μl of cells were added to each well of a transparent 96-well plate. 0 / 4 μg / ml of purified Fc protein of IT1-RBD1 / RBD2 / RBD3 was added to each well. After being placed in a cell culture incubator for two hours, 50 μg / ml of concanavalin A (ConA) (Aladdin, Shanghai, China) was added to each well as an activation group or an equal volume of endotoxin-free water as an inactivation group, and placed in a cell culture incubator for 18-24 hours. After the reaction was completed, an opaque 96-well plate (costar, ME, USA) was taken, and 50 μl of Quanti-luc reagent (Invivogen, CA, USA) and 20 μl of reaction mixture were added to each well. After adding and mixing, the signal was immediately detected using a multifunctional microplate reader.

[0187] like Fig.36 As shown in the figure, under the conditions of 50 μg / ml ConA activation and non-activation, the NFKB signal changes of Jurkat-dual cells were added with 4 μg / ml Fc protein of different IT1-RBD segments. The above results show that the purified IT1-RBD1-Fc protein can inhibit the NFKB proliferation signal of Jurkat-dual cells under the conditions of ConA activation and non-activation, and the inhibitory effect gradually weakens as the sequence gradually shortens.

[0188] 3. Flow cytometry demonstrated that the purified IT1-RBD1-Fc recombinant protein could reduce the killing of kidney-derived H3K293 cells by human peripheral blood mononuclear cells (PBMC).

[0189] CD3 and CD28 antibodies (Invitrogen, CA, USA) were mixed and diluted with PBMC (ATCC, VA, USA) to a final concentration of 1 μg / ml to activate T cells and cultured overnight. The next day, PBMC and 293E wild-type (ATCC, VA, USA) / ITPRIPL1 overexpressing cells were counted and the cell number was adjusted to 1x106 / ml. The control group added 100 μl of 293E wild-type / ITPRIPL1 overexpressing cells and 100 μl of culture medium. The experimental group added 100 μl of PBMC and another cell to a 96-well plate (costar, ME, USA). In the experimental group, 3 groups of wild-type 293E cells were added with 2 μg / ml of IT1-RBD1 / RBD2 / RBD3-Fc protein and incubated in an incubator for 6 hours. The 96-well plate was removed, the cells were absorbed, placed in an EP tube (Axygen, CA, USA), and the supernatant was discarded after centrifugation at 400 rcf for 5 minutes. Resuspend the washed cells with 500 μL of cell staining buffer (Invitrogen, CA, USA), repeat centrifugation and washing. Dilute CD45-APC antibody (Invitrogen, CA, USA) with cell staining buffer at 1:20, add 200 μL of the mixture to each EP tube and resuspend, incubate at room temperature for 30 minutes with slow shaking. Centrifuge at 400 rcf for 5 minutes, discard the supernatant, resuspend the washed cells with 1 ml of binding buffer (Biyuntian, Shanghai, China); repeat centrifugation and washing. The unstained group without PBMC, the double-stained group without PBMC, the unstained group with PBMC, the group with PBMC single-stained with Annexin V-FITC, the group with PBMC single-stained with PI, the group with PBMC double-stained, and the double-stained groups with IT1 protein were set up. According to the conditions, 100 μL of binding buffer, 5 μL of Annexin V-FITC (Biyuntian, Shanghai, China) and 10 μL of PI (Biyuntian, Shanghai, China) were added respectively, and incubated at room temperature with slow shaking for 15 min. Then 400 μL of binding buffer was added to each group, and the cells were transferred to flow tubes (Falcon, NY, USA) and loaded into a flow cytometer (Miltenyi Biotec, Cologne, Germany).

[0190] Fig.37 (a) shows the classification of 293E cells based on CD45. Fig.37 (b) is the relative killing activity of PBMC calculated based on the apoptosis data of each group under different ITPRIPL1 expression and different protein conditions. Fig.38 for Fig.37 The above results show that the purified IT1-RBD1-Fc recombinant protein can reduce the killing of human peripheral blood mononuclear cells (PBMC) on kidney-derived H3K293 cells, and as the sequence is shortened, the reduction effect gradually weakens.

[0191] 4. Immunoblotting experiments showed that ITPRIPL1-RBD recombinant protein and purified IT1-RBD1-Fc recombinant protein have the function of inhibiting the ZAP70 and Akt pathways downstream of CD3E.

[0192] The cultured Jurkat cells (ATCC, VA, USA) were counted, 4x106 cells were taken into a 15ml centrifuge tube (Corning, NY, USA), centrifuged at 800rpmx4 minutes, the supernatant was discarded, and the cells were resuspended in serum-free RPMI1640 medium (Mei Lun, Dalian, China), placed in an incubator for starvation culture for 3 hours, centrifuged at 800rpmx4 minutes, resuspended in 4 ml complete medium (Mei Lun, Dalian, China), and 1 ml was taken into each well of a 12-well plate (Corning, NY, USA), and each well was added with: no treatment; 4 μg / ml IT1-RBD protein; 4 μg / ml RBD1-Fc protein; 4 μg / ml RBD2-Fc protein. After thorough mixing, the cells were placed in an incubator for 10 minutes, then taken out, and the cells were transferred to a 1.5ml EP tube (Axygen, CA, USA), centrifuged at 800rpmx4 minutes, resuspended in PBS and centrifuged, and the washing was repeated. After centrifugation, the supernatant was discarded, and RIPA lysis buffer (Biyuntian, Shanghai, China) and protease inhibitors, phosphatase inhibitors, and PMSF (Kangchen, Shanghai, China) were prepared at a ratio of 1:100, and 80 μl of mixed lysis buffer was added to each tube of cells. Each EP tube was frozen and thawed three times on liquid nitrogen-ice, and centrifuged at 12000rpm and 4 degrees Celsius for 15 minutes after the last thawing. After centrifugation, the supernatant was taken, and the supernatant after centrifugation: 5x loading buffer (Biyuntian, Shanghai, China) was prepared into each cell sample at a ratio of 4:1, and placed in a 100 degree Celsius metal bath for 10 minutes to denature to obtain a protein sample. Then, according to the instructions, a 10% PAGE gel (Yazyme, Shanghai, China) was prepared in a gel plate (Bio-Rad, CA, USA), and the prepared gel was placed in an electrophoresis tank (Bio-Rad, CA, USA), and the power supply (Bio-Rad, CA, USA) was connected to run the strip through the concentrated gel at a constant voltage of 80 volts, and the separation gel was run at a constant voltage of 120 volts. When the band runs to the bottom of the separation gel, the membrane is transferred by wet transfer method, and the membrane is transferred in a transfer tank (Bio-Rad, CA, USA) at a constant current of 350 mA for 90 minutes. After the transfer is completed, the membrane is cut according to the mass size of Akt, ZAP70 and GAPDH proteins. The rapid blocking solution (Yazyme, Shanghai, China) is used for blocking for ten minutes, and the corresponding bands are incubated with pAkt-specific rabbit antibody (CST, MA, USA), Akt-specific rabbit antibody (CST, MA, USA), pZAP70-specific rabbit antibody (CST, MA, USA), and GAPDH antibody (Conson, Shanghai, China) respectively, and the four-step overnight. The next day, after washing with TBST, the specific anti-rabbit secondary antibody (Conson, Shanghai, China) diluted with 5% skim milk powder (Sangon, Shanghai, China) dissolved in TBS was incubated at room temperature for one hour, and after washing with TBST, it was placed in a mixed luminescent solution (Shenger, Shanghai, China) for one minute and exposed under a gel imager (Bio-Rad, CA, USA).

[0193] Fig.39(a) and (b) are the expressions of phosphorylated Akt and phosphorylated ZAP70 after adjustment with GAPDH as internal reference in immunoblotting, respectively. Akt phosphorylation and ZAP70 phosphorylation were reduced to a certain extent after being treated with ITPRIPL1-RBD recombinant protein and purified IT1-RBD-Fc protein, and the phosphorylation reduction of IT1-RBD1-Fc recombinant protein was more obvious than that of IT1-RBD2-Fc protein. The experimental results show that ITPRIPL1-RBD recombinant protein and purified IT1-RBD1-Fc protein have the effect of reducing Akt and ZAP70 phosphorylation downstream of CD3E, indicating that they have the function of inhibiting the corresponding T cell pathway.

[0194] In summary, the present invention discloses a newly identified natural membrane protein ITPRIPL1 that binds to the extracellular region of CD3ε, and reveals the signal transduction changes that control T cell activation after ITPRIPL1 binds to CD3ε. This suggests that antibodies that have been found to bind to CD3ε in the past may simulate or affect the natural ligand function of ITPRIPL1 to a certain extent. The discovery of CD3ε and ITPRIPL1 as a pair of immune checkpoint receptor ligands provides a new perspective for a deeper understanding of the maintenance of the body's immune homeostasis and the immune escape mechanism of tumor cells.

[0195] When the embodiments give numerical ranges, it should be understood that, unless otherwise specified in the present invention, both endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those generally understood by those skilled in the art. In addition to the specific methods, equipment, and materials used in the embodiments, according to the grasp of the prior art by those skilled in the art and the record of the present invention, any methods, equipment, and materials of the prior art similar or equivalent to the methods, equipment, and materials described in the embodiments of the present invention can also be used to realize the present invention.

Claims

1. Use of an ITPRIPL1 regulator in the preparation of an anti-tumor drug, wherein the regulator is used to reduce the expression or function of the ITPRIPL1 gene or protein of tumor cells.

2. The use according to claim 1, characterized in that The tumor cells are tumor cells expressing ITPRIPL1.

3. The use according to claim 1, characterized in that The ITPRIPL1 regulator is selected from any one or more of the following: (1) A gene editing system that knocks out or mutates the ITPRIPL1 gene in cells; (2) RNA molecules that reduce the expression level of the ITPRIPL1 gene; (3) Antibodies that recognize and bind to ITPRIPL1.

4. The use according to claim 3, characterized in that The gene editing system is a CRISPR / Cas9 gene editing system, and the target sequence used for the CRISPR / Cas9 gene editing system is selected from any one of the sequences shown in SEQ ID NO:11-13.

5. The use according to claim 4, characterized in that In the gene editing system, the oligo DNA sequence used to encode sgRNA is selected from SEQ ID NO: 14-19.

6. The use according to claim 3, characterized in that: The antibody that recognizes and binds to ITPRIPL1 recognizes and binds to the extracellular region of the ITPRIPL1 protein and can block the binding between ITPRIPL1 and CD3.

7. The use according to claim 6, characterized in that The antibody that recognizes and binds to ITPRIPL1 recognizes and binds to ITPRIPL1 recombinant protein, and the ITPRIPL1 recombinant protein comprises: a functional fragment in the extracellular region of ITPRIPL1 protein that can bind to CD3ε or NRP2 protein.

8. The use according to claim 7, characterized in that The sequence of the functional fragment is selected from any one of SEQ ID NO: 1, 2, 4, or a derivative sequence thereof, and the derivation method includes: replacing, deleting or inserting one or more amino acids without changing the function of the sequence.

9. The use according to claim 8, wherein the antibody that recognizes and binds to ITPRIPL1 is prepared by using the ITPRIPL1 recombinant protein according to claim 7 as an immunogen; And / or, the antibody that recognizes and binds to ITPRIPL1 is a polyclonal antibody, a monoclonal antibody, a single-chain antibody, an antigen-binding domain, a bispecific antibody, a multispecific antibody, or an antigen-binding portion in a chimeric antigen receptor.

10. The use according to any one of claims 1 to 9, characterized in that: The tumor is a solid tumor or a hematological tumor; the solid tumor includes: glioma, lung cancer, head and neck cancer, gastric cancer, colorectal cancer, thyroid cancer, esophageal cancer, urothelial cancer, testicular cancer, breast cancer, cervical cancer, endometrial cancer, melanoma, pancreatic cancer or liver cancer; the hematological tumor includes: leukemia or lymphoma.